

ONYX Healthcare Inc. and Subsidiaries  
Consolidated Financial Statements and  
Independent Auditor's Review Report  
For the First Quarter of 2022 and 2021  
(Stock code: 6569)

Company address: 2F, No. 135, Lane 235, Baoqiao Road,  
Xindian District, New Taipei City  
TEL: (02)8919-2188

For the convenience of readers and for information purpose only, the independent auditors' review report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language independent auditors' review report and financial statements shall prevail.

ONYX Healthcare Inc. and Subsidiaries  
Consolidated Financial Statements and Independent Auditor's Review Report for the  
First Quarter of 2022 and 2021  
Table of Contents

<u>Item</u>	<u>Page</u>
1. Cover page	1
2. Table of contents	2~3
3. Independent auditor's review report	4~5
4. Consolidated balance sheet	6~7
5. Consolidated statement of comprehensive income	8~9
6. Consolidated statement of changes in equity	10
7. Consolidated cash flow statement	11~12
8. Notes to consolidated financial statements	13~62
(1) Company history	13
(2) Financial statement approval date and procedures	13
(3) Application of new and amended standards and interpretations	13~14
(4) Summary of significant accounting policies	14~16
(5) Sources of uncertainty to significant accounting judgments, estimates, and assumptions	16
(6) Notes to major accounts	16~40
(7) Related party transactions	40~45

<u>Item</u>	<u>Page</u>
(8) Pledged assets	45
(9) Major contingent liabilities and unrecognized contractual commitments	45
(10) Losses from major disasters	46
(11) Major post-balance sheet events	46
(12) Others	46~59
(13) Other disclosures	59~60
(14) Segment information	60~62

## Independent Auditor's Review Report

(111)-Cai-Shen-Bao-Zi No. 22000044

To stakeholders of ONYX Healthcare Inc.:

### **Preamble**

We have reviewed the accompanying consolidated balance sheet of ONYX Healthcare Inc. and subsidiaries (referred to as "ONYX Group" below) as of March 31, 2022 and 2021, the consolidated statement of comprehensive income, consolidated statement of changes in equity, and consolidated cash flow statement from January 1 to March 31, 2022 and 2021, and notes to consolidated financial statements (including a summary of significant accounting policies). It is the responsibility of the management to prepare and ensure fair presentation of consolidated financial statements in accordance with Regulations Governing the Preparation of Financial Reports by Securities Issuers, and the version of IAS 34 - "Interim Financial Reporting" approved by the Financial Supervisory Commission. Our responsibility as auditor is to form a conclusion based on our review.

### **Scope**

Except for the issues discussed in the "Basis of reservation" paragraph, we, the auditors, have performed the review in accordance with Statement on Auditing Standards No. 65 - "Financial Statement Review." The procedures executed in our review of consolidated financial statements include inquiry (mainly with employees responsible for financial and accounting affairs), analysis, and other review-related processes. The scope of financial statement review is significantly smaller than a financial statement audit, therefore we may not be able to detect all material issues through the steps we have taken, and are therefore unable to provide an audit opinion.

### **Basis of reservation**

As mentioned in Note 4(3) of the consolidated financial statements, some of the non-material subsidiaries were consolidated using financial statements for the corresponding periods that were not reviewed by CPAs. As of March 31, 2022 and 2021, these subsidiaries aggregately reported total assets of NT\$48,257 thousand and NT\$47,366 thousand that represented 2% and 3% of consolidated total assets, and total liabilities of NT\$7,194 thousand and NT\$7,704 thousand that represented 1% and 2% of consolidated total liabilities, respectively. These subsidiaries also reported total comprehensive income of NT\$(398) thousand and NT\$(720) thousand that represented (1%) and (4%) of consolidated total comprehensive income for the periods January 1 to March 31, 2022 and 2021, respectively.

## **Reservations**

Base on our review and the review reports of other CPAs (please refer to the Other issues paragraph), we found that none of the material disclosures of the consolidated financial statements mentioned above exhibited any misstatement that did not conform with Regulations Governing the Preparation of Financial Reports by Securities Issuers or the version of IAS 34 - "Interim Financial Reporting" approved by the Financial Supervisory Commission, or compromised the fair view of the consolidated financial position of ONYX Group as of March 31, 2022 and 2021, or the consolidated financial performance and consolidated cash flow for the periods January 1 to March 31, 2022 and 2021, except for the issues discussed in the "Basis of reservation" paragraph, where financial statements of certain non-material subsidiaries had yet to be reviewed by CPAs, and may cause adjustments to the consolidated financial statements if they were CPA-reviewed.

## **Other issues - reviews by other CPAs**

Amongst the equity-accounted business investments presented in the consolidated financial statements of ONYX Group, some of which had financial statements reviewed by other CPAs that we did not take part in. Therefore, amounts presented in the consolidated financial statements mentioned above in regards to such businesses were based on auditor-reviewed reports of other CPAs. As of March 31, 2022 and 2021, balances of the abovementioned equity-accounted investments totaled NT\$575,109 thousand and NT\$549,534 thousand, representing 28% and 38% of consolidated total assets, respectively. For the periods from January 1 to March 31, 2022 and 2021, comprehensive income recognized from the abovementioned companies totaled NT\$13,834 thousand and NT\$11,143 thousand, representing 31% and 69% of consolidated comprehensive income, respectively.

PwC Taiwan

LIN,CHUN-YAO

CPA

Weng, Shih-Rong

(Formerly known as) Securities and Futures Commission, The Ministry of Finance  
Approval reference: (85)-Tai-Cai-Zheng-(VI) No. 68702

(Formerly known as) Securities and Futures Commission, The Ministry of Finance  
Approval reference: (88)-Tai-Cai-Zheng-(VI) No. 95577

May 3, 2022

ONYX Healthcare Inc. and Subsidiaries

Consolidated balance sheet

As of March 31, 2022, December 31, 2021, and March 31, 2021

(Consolidated balance sheets as of March 31, 2022 and 2021, were auditor-reviewed and not audited according to generally accepted audit principles)

Unit: NT\$ thousand

Assets	Note	March 31, 2022		December 31, 2021		March 31, 2021		
		Amount	%	Amount	%	Amount	%	
<b>Current assets</b>								
1100	Cash and cash equivalents	6(1)	\$ 457,529	23	\$ 182,893	11	\$ 392,400	27
1110	Financial assets at fair value through profit or loss - current	6(2)	8,269	-	10,125	1	5,325	1
1170	Net accounts receivable	6(3)	235,705	12	202,843	12	104,473	7
1180	Accounts receivable - related parties, net	7	6,105	-	2,673	-	1,071	-
1200	Other receivables		3,743	-	4,564	-	1,868	-
1220	Current income tax asset		6,301	-	6,092	-	-	-
130X	Inventory	6(4)	281,658	14	271,219	16	187,872	13
1410	Prepayments		18,959	1	16,486	1	18,428	1
1470	Other current assets	8	1,135	-	1,520	-	13,700	1
11XX	<b>Total current assets</b>		<u>1,019,404</u>	<u>50</u>	<u>698,415</u>	<u>41</u>	<u>725,137</u>	<u>50</u>
<b>Non-current assets</b>								
1510	Financial assets at fair value through profit or loss - non-current	6(2)	32,197	2	36,406	2	42,364	3
1517	Financial assets at fair value through other comprehensive income - non-current	6(5)	30,806	2	32,381	2	2,381	-
1550	Equity-accounted investments	6(6)	575,109	28	561,275	33	549,534	38
1600	Property, plant and equipment	6(7)	22,457	1	24,321	2	31,971	2
1755	Right-of-use assets	6(8) and 7	40,757	2	44,683	3	46,202	3
1760	Investment property - net	6(10), 7, and 8	277,238	14	277,645	16	-	-
1780	Intangible assets		5,690	-	4,589	-	4,715	1
1840	Deferred income tax assets		17,831	1	18,994	1	14,642	1
1900	Other non-current assets	6(7) and 8	3,402	-	3,224	-	30,507	2
15XX	<b>Total non-current assets</b>		<u>1,005,487</u>	<u>50</u>	<u>1,003,518</u>	<u>59</u>	<u>722,316</u>	<u>50</u>
1XXX	<b>Total assets</b>		<u>\$ 2,024,891</u>	<u>100</u>	<u>\$ 1,701,933</u>	<u>100</u>	<u>\$ 1,447,453</u>	<u>100</u>
<b>Current liabilities</b>								
2100	Short-term loans	6(11)	\$ 105,000	5	\$ 105,000	6	\$ -	-
2120	Financial liabilities at fair value through profit or loss - current	6(12)	-	-	-	-	116	-
2130	Contractual liabilities - current	6(21)	85,653	4	75,755	5	50,612	3
2170	Accounts payable		93,315	5	91,857	5	69,273	5
2180	Accounts payable - related parties	7	34,597	2	32,673	2	23,856	2
2200	Other payables	6(13) and 7	63,624	3	73,754	4	80,477	6
2230	Current income tax liabilities		27,175	1	18,846	1	39,445	3
2250	Liability reserves - current	6(16)	6,795	-	6,272	-	6,406	-

(Continued next page)

ONYX Healthcare Inc. and Subsidiaries

Consolidated balance sheet

As of March 31, 2022, December 31, 2021, and March 31, 2021

(Consolidated balance sheets as of March 31, 2022 and 2021, were auditor-reviewed and not audited according to generally accepted audit principles)

Unit: NT\$ thousand

	Liabilities and equity	Note	March 31, 2022		December 31, 2021		March 31, 2021	
			Amount	%	Amount	%	Amount	%
2280	Lease liabilities - current	7	9,506	1	10,513	1	8,202	1
2320	Long-term liabilities due within 1 year or 1 business cycle	6(14)	10,591	1	10,744	1	-	-
2399	Other current liabilities - others		5,541	-	5,896	-	5,434	-
21XX	<b>Total current liabilities</b>		<u>441,797</u>	<u>22</u>	<u>431,310</u>	<u>25</u>	<u>283,821</u>	<u>20</u>
	<b>Non-current liabilities</b>							
2527	Contractual liabilities - non-current	6(21)	66,129	3	42,138	3	50,866	3
2540	Long-term loans	6(14)	152,522	7	155,043	9	-	-
2550	Liability reserves - non-current	6(16)	2,338	-	1,999	-	1,954	-
2570	Deferred income tax liabilities		1,409	-	1,278	-	754	-
2580	Lease liabilities - non-current	7	31,713	2	34,251	2	38,149	3
2645	Guarantee deposits received	7	1,148	-	1,148	-	-	-
25XX	<b>Total non-current liabilities</b>		<u>255,259</u>	<u>12</u>	<u>235,857</u>	<u>14</u>	<u>91,723</u>	<u>6</u>
2XXX	<b>Total liabilities</b>		<u>697,056</u>	<u>34</u>	<u>667,167</u>	<u>39</u>	<u>375,544</u>	<u>26</u>
	<b>Equity</b>							
	<b>Equity attributable to parent company shareholders</b>							
	Share capital	6(18)						
3110	Common share capital		302,612	15	302,612	18	275,102	19
3140	Share capital received in advance		237,600	12	-	-	-	-
	Capital reserves	6(17) (19)						
3200	Capital reserves		473,044	23	462,673	27	481,470	33
	Retained earnings	6(20)						
3310	Legal reserves		118,655	6	118,655	7	101,948	7
3320	Special reserves		44,993	2	44,993	3	40,263	3
3350	Unappropriated earnings		188,801	9	146,858	8	209,425	15
	Other equity items							
3400	Other equity items		(46,356)	(2)	(49,896)	(3)	(45,499)	(4)
31XX	<b>Total equity attributable to parent company shareholders</b>		<u>1,319,349</u>	<u>65</u>	<u>1,025,895</u>	<u>60</u>	<u>1,062,709</u>	<u>73</u>
36XX	<b>Non-controlling equity</b>	4(3)	<u>8,486</u>	<u>1</u>	<u>8,871</u>	<u>1</u>	<u>9,200</u>	<u>1</u>
3XXX	<b>Total equity</b>		<u>1,327,835</u>	<u>66</u>	<u>1,034,766</u>	<u>61</u>	<u>1,071,909</u>	<u>74</u>
	Major contingent liabilities and unrecognized contractual commitments	9						
	Major post-balance sheet date events	11						
3X2X	<b>Total liabilities and equity</b>		<u>\$ 2,024,891</u>	<u>100</u>	<u>\$ 1,701,933</u>	<u>100</u>	<u>\$ 1,447,453</u>	<u>100</u>

The attached Notes to consolidated financial statements are part of this consolidated financial statement and should be read in conjunction.

Chairman: Chuang, Yung-Shun

Manager: Wang, Feng-Hsiang

Head of Accounting: Yang, Hsiang-Chih

ONYX Healthcare Inc. and Subsidiaries  
Consolidated statement of comprehensive income  
January 1 to March 31, 2022 and 2021

(Reviewed only; not audited in accordance with generally accepted audit principles)

Unit: NT\$ thousand

(except earnings per share, which are presented in NTD)

	Item	Note	January 1 to March 31, 2022		January 1 to March 31, 2021	
			Amount	%	Amount	%
4000	Operating revenues	6(21) and 7	\$ 419,208	100	\$ 273,277	100
5000	Operating costs	6(4)(24) (25) and 7	( 299,669)	( 71)	( 190,205)	( 70)
5900	Gross profit		<u>119,539</u>	<u>29</u>	<u>83,072</u>	<u>30</u>
	Operating expenses	6(24) (25) and 7				
6100	Selling expenses		( 45,602)	( 11)	( 34,495)	( 12)
6200	Administrative expenses		( 21,127)	( 5)	( 18,322)	( 7)
6300	R&D expenses		( 20,729)	( 5)	( 26,863)	( 10)
6450	Expected credit impairment loss/reversal gain	12(2)	474	-	247	-
6000	Total operating expenses		<u>( 86,984)</u>	<u>( 21)</u>	<u>( 79,433)</u>	<u>( 29)</u>
6900	Operating profit		<u>32,555</u>	<u>8</u>	<u>3,639</u>	<u>1</u>
	Non-operating income and expenses					
7100	Interest income		1	-	37	-
7010	Other income	6(22) and 7	6,718	1	1,305	-
7020	Other gains and losses	6(23)	624	-	1,713	1
7050	Financial costs		( 792)	-	( 156)	-
7060	Share of profits/losses on equity- accounted associated companies and joint ventures		<u>11,946</u>	<u>3</u>	<u>11,149</u>	<u>4</u>
7000	Total non-operating income and expenses		<u>18,497</u>	<u>4</u>	<u>14,048</u>	<u>5</u>
7900	<b>Pre-tax profit</b>		<u>51,052</u>	<u>12</u>	<u>17,687</u>	<u>6</u>
7950	Income tax expense	6(26)	( 9,494)	( 2)	( 1,025)	-
8200	<b>Current net income</b>		<u>\$ 41,558</u>	<u>10</u>	<u>\$ 16,662</u>	<u>6</u>
	<b>Other comprehensive income (net)</b>					
	<b>Items not reclassified into profit or loss</b>					
8316	Unrealized gain/loss on valuation of equity instruments at fair value through other comprehensive income	6(5)	(\$ 1,575)	-	\$ -	-
8320	Share of other comprehensive income from equity-accounted associated companies and joint ventures - not reclassified into profit or loss		<u>1,612</u>	-	( 29)	-
8310	Items not reclassified into profit or loss - total		<u>37</u>	-	( 29)	-

(Continued next page)



ONYX Healthcare Inc. and Subsidiaries  
Consolidated statement of comprehensive income  
January 1 to March 31, 2022 and 2021

(Reviewed only; not audited in accordance with generally accepted audit principles)

Unit: NT\$ thousand  
(except earnings per share, which are presented in NTD)

Item	Note	January 1 to March 31, 2022		January 1 to March 31, 2021	
		Amount	%	Amount	%
<b>Items likely to be reclassified into profit or loss</b>					
8361					
	Financial statement translation differences arising from foreign operations	4,034	1	( 625)	-
8370					
	Share of other comprehensive income from equity-accounted associated companies and joint ventures - likely to be reclassified into profit or loss	276	-	23	-
8399					
	Income tax on items that are likely to be reclassified into profit or loss	( 807)	-	125	-
8360					
	Items likely to be reclassified into profit or loss - total	3,503	1	( 477)	-
8300					
	<b>Other comprehensive income (net)</b>	<u>\$ 3,540</u>	<u>1</u>	<u>(\$ 506)</u>	<u>-</u>
8500					
	<b>Total comprehensive income for the current period</b>	<u>\$ 45,098</u>	<u>11</u>	<u>\$ 16,156</u>	<u>6</u>
	Net income (loss) attributable to:				
8610					
	Parent company shareholders	\$ 41,943	10	\$ 17,375	6
8620					
	Non-controlling equity	( 385)	-	( 713)	-
	Total	<u>\$ 41,558</u>	<u>10</u>	<u>\$ 16,662</u>	<u>6</u>
	Comprehensive income attributable to:				
8710					
	Parent company shareholders	\$ 45,483	11	\$ 16,869	6
8720					
	Non-controlling equity	( 385)	-	( 713)	-
	Total	<u>\$ 45,098</u>	<u>11</u>	<u>\$ 16,156</u>	<u>6</u>
	EPS				
9750					
	Basic earnings per share	<u>\$</u>	<u>1.39</u>	<u>\$</u>	<u>0.57</u>
9850					
	Diluted earnings per share	<u>\$</u>	<u>1.38</u>	<u>\$</u>	<u>0.57</u>

The attached Notes to consolidated financial statements are part of this consolidated financial statement and should be read in conjunction.

Chairman: Chuang, Yung-Shun

Manager: Wang, Feng-Hsiang

Head of Accounting: Yang, Hsiang-Chih

ONYX Healthcare Inc. and Subsidiaries  
Consolidated statement of changes in equity  
January 1 to March 31, 2022 and 2021

(Reviewed only; not audited in accordance with generally accepted audit principles)

Unit: NTS thousand

Note	Equity attributable to parent company shareholders										Non-controlling equity	Total
	Share capital			Retained earnings			Other equity items					
	Common share capital	Share capital received in advance	Capital reserves	Legal reserves	Special reserves	Unappropriated earnings	Financial statement translation differences arising from foreign operations	Unrealized gains/losses on financial assets at fair value through other comprehensive income	Total	Total		
<u>January 1 to March 31, 2021</u>												
		\$ 275,102	\$ -	\$ 478,566	\$ 101,948	\$ 40,263	\$ 192,050	(\$ 7,984)	(\$ 37,009)	\$ 1,042,936	\$ 9,913	\$ 1,052,849
		-	-	-	-	-	17,375	-	-	17,375	( 713 )	16,662
		-	-	-	-	-	-	( 477 )	( 29 )	( 506 )	-	( 506 )
		-	-	-	-	-	17,375	( 477 )	( 29 )	16,869	( 713 )	16,156
	6(17)(19)	-	-	2,904	-	-	-	-	-	2,904	-	2,904
		\$ 275,102	\$ -	\$ 481,470	\$ 101,948	\$ 40,263	\$ 209,425	(\$ 8,461)	(\$ 37,038)	\$ 1,062,709	\$ 9,200	\$ 1,071,909
<u>January 1 to March 31, 2022</u>												
		\$ 302,612	\$ -	\$ 462,673	\$ 118,655	\$ 44,993	\$ 146,858	(\$ 12,500)	(\$ 37,396)	\$ 1,025,895	\$ 8,871	\$ 1,034,766
		-	-	-	-	-	41,943	-	-	41,943	( 385 )	41,558
		-	-	-	-	-	-	3,503	37	3,540	-	3,540
		-	-	-	-	-	41,943	3,503	37	45,483	( 385 )	45,098
	6(18)	-	237,600	-	-	-	-	-	-	237,600	-	237,600
	6(17)(19)	-	-	8,174	-	-	-	-	-	8,174	-	8,174
	6(17)(19)	-	-	2,197	-	-	-	-	-	2,197	-	2,197
		\$ 302,612	\$ 237,600	\$ 473,044	\$ 118,655	\$ 44,993	\$ 188,801	(\$ 8,997)	(\$ 37,359)	\$ 1,319,349	\$ 8,486	\$ 1,327,835

The attached Notes to consolidated financial statements are part of this consolidated financial statement and should be read in conjunction.

Chairman: Chuang, Yung-Shun

Manager: Wang, Feng-Hsiang

Head of Accounting: Yang, Hsiang-Chih

ONYX Healthcare Inc. and Subsidiaries  
Consolidated cash flow statement  
January 1 to March 31, 2022 and 2021

(Reviewed only; not audited in accordance with generally accepted audit principles)

Unit: NT\$ thousand

	Note	January 1 to March 31, 2022	January 1 to March 31, 2021
<u>Cash flow from operating activities</u>			
Pre-tax profit for the current period		\$ 51,052	\$ 17,687
Adjustments			
Income, expenses, and losses			
Depreciation	6(7)(8) (24)	6,826	5,852
Depreciation of investment properties (presented as other gains and losses)	6(10)(23)	407	-
Amortization	6(24)	483	419
Expected credit impairment loss/reversal gain	12(2)	( 474 )	( 247 )
Loss (gain) on financial assets or liabilities at fair value through profit or loss	6(2)(12) (23)	6,065	( 3,800 )
Interest expenses		792	156
Interest income		( 1 )	( 37 )
Dividend income	6(22)	( 3,367 )	-
Share-based payment - remuneration	6(17)	10,371	2,904
Share of profit from equity-accounted associated companies		( 11,946 )	( 11,149 )
Loss on lease amendment	6(8)(23)	-	6
Change in assets/liabilities related to operating activities			
Net change in assets related to operating activities			
Notes receivable		-	49
Accounts receivable		( 32,841 )	47,931
Accounts receivable - related parties		( 3,432 )	( 423 )
Other receivables		821	1,256
Inventory		( 10,439 )	( 8,567 )
Prepayments		( 2,473 )	( 1,915 )
Other current assets		413	-
Net change in liabilities related to operating activities			
Contractual liabilities		33,889	( 6,599 )
Accounts payable		1,458	10,658
Accounts payable - related parties		1,924	( 14,004 )
Other payables		( 8,610 )	3,713
Other payables - related parties		47	( 175 )
Liability reserves		862	( 254 )
Other current liabilities		( 355 )	1,346

(Continued next page)

ONYX Healthcare Inc. and Subsidiaries  
Consolidated cash flow statement  
January 1 to March 31, 2022 and 2021

(Reviewed only; not audited in accordance with generally accepted audit principles)

Unit: NT\$ thousand

	<u>Note</u>	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Cash inflow from operating activities		41,472	44,807
Interests received		1	37
Dividends received		3,367	-
Interests paid		( 783 )	( 156 )
Income tax paid		( 379 )	( 7,232 )
Net cash inflow from operating activities		<u>43,678</u>	<u>37,456</u>
<u>Cash flow from investing activities</u>			
Acquisition of equity-accounted investments		\$ -	( \$ 1,289 )
Acquisition of property, plant, and equipment	6(28)	( 3,840 )	( 4,445 )
Acquisition of intangible assets		( 1,584 )	-
(Increase) decrease in guarantee deposits paid (presented as other current assets)		( 178 )	345
Increase in prepayments for real estate property (presented as other non-current assets)	6(7)	-	( 28,008 )
Net cash outflow from investing activities		<u>( 5,602 )</u>	<u>( 33,397 )</u>
<u>Cash flow from financing activities</u>			
Repayment of long-term loan	6(29)	( 2,674 )	-
Repayment of lease principal	6(29)	( 2,331 )	( 3,430 )
Cash issue	6(18)	<u>237,600</u>	-
Net cash inflow (outflow) from financing activities		<u>232,595</u>	<u>( 3,430 )</u>
Exchange rate impact		<u>3,965</u>	<u>( 593 )</u>
Increase in cash and cash equivalents for the current period		274,636	36
Opening cash and cash equivalents balance	6(1)	<u>182,893</u>	<u>392,364</u>
Closing cash and cash equivalents balance	6(1)	<u>\$ 457,529</u>	<u>\$ 392,400</u>

The attached Notes to consolidated financial statements are part of this consolidated financial statement and should be read in conjunction.

Chairman: Chuang, Yung-Shun

Manager: Wang, Feng-Hsiang

Head of Accounting: Yang, Hsiang-Chih

ONYX Healthcare Inc. and Subsidiaries  
Notes to consolidated financial statements  
For the First Quarter of 2022 and 2021

(Reviewed only; not audited in accordance with generally accepted audit principles)

Unit: NT\$ thousand  
(unless specified otherwise)

I. Corporate history

ONYX Healthcare Inc. (the "Company") was incorporated on February 2, 2010 in the Republic of China. The Company and its subsidiaries (collectively referred to as "Group" below) are mainly involved in the design, manufacturing, and trading of medical computers and peripherals. AAEON Technology Inc. holds 50% equity ownership in the Company, whereas ASUSTeK Computer Inc. is the Group's ultimate parent.

II. Financial statement approval date and procedures

This consolidated financial report was passed during the board of directors meeting dated May 3, 2022.

III. Application of new standards, amendments and interpretations

(I) Impacts of adopting new and amended International Financial Reporting Standards (IFRS) approved by the Financial Supervisory Commission (FSC)

The following is a list of new/amended/modified IFRSs and interpretations approved by FSC that are applicable for the 2022 financial year:

<u>New/amended/modified standards and interpretations</u>	<u>Effective date of IASB announcement</u>
Amendments to IFRS 3 regarding "Reference to the Conceptual Framework"	January 1, 2022
Amendments to IAS 16 regarding "Property, Plant and Equipment: Proceeds before Intended Use"	January 1, 2022
Amendment to IAS 37 regarding "Onerous Contracts - Cost of Fulfilling a Contract"	January 1, 2022
Improvements for years 2018-2020	January 1, 2022

After a thorough assessment, the Group expects no material financial or performance impact from the above standards and interpretations.

(II) Impacts of adopting new and amended IFRSs not yet approved by FSC

None.

(III) Impacts of IFRS changes announced by International Accounting Standards Board (IASB) but not yet approved by FSC

The following is a list of new/amended/modified IFRSs announced by IASB but not approved by FSC:

<u>New/amended/modified standards and interpretations</u>	<u>Effective date of IASB announcement</u>
Amendments to IFRS 10 and IAS 28 regarding "Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture"	Pending final decision from IASB
IFRS 17 - Insurance Contracts	January 1, 2023
Amendments to IFRS 17 - "Insurance Contracts"	January 1, 2023
Amendments to IFRS 17 - "Initial Application of IFRS 17 and IFRS 9 - Comparative Information"	January 1, 2023
Amendments to IAS 1 regarding "Classification of Liabilities as Current or Non-current"	January 1, 2023
Amendments to IAS 1 regarding "Disclosure of Accounting Policies"	January 1, 2023
Amendments to IAS 8 regarding "Definition of Accounting Estimates"	January 1, 2023
Amendments to IAS 12 regarding "Deferred Tax related to Assets and Liabilities arising from a Single Transaction"	January 1, 2023

After a thorough assessment, the Group expects no material financial or performance impact from the above standards and interpretations.

IV. Summary of significant accounting policies

Except for the statement of compliance, basis of preparation, basis of consolidation, and new explanations provided below, all other significant accounting policies are unchanged from Note 4 of the 2021 consolidated financial statements. Unless otherwise stated, the following policies were applied consistently in all reporting periods.

(I) Statement of compliance

1. The consolidated financial statements have been prepared in accordance with Regulations Governing the Preparation of Financial Reports by Securities Issuers and FSC-approved IAS 34 - "Interim Financial Reporting."
2. These consolidated financial statements should be read in conjunction with the 2021 consolidated financial statements.

(II) Basis of preparation

1. This consolidated financial report is prepared based on historical cost, except for items including financial assets and liabilities at fair value through profit or loss (including

derivatives) and financial assets at fair value through other comprehensive income.

2. Preparation of financial report that complies with the version of International Financial Reporting Standards, International Accounting Standards and interpretations approved by the FSC (collectively referred to as "IFRSs" below) involves some use of critical accounting estimates, and the management is required to exercise some judgment when applying the Company's accounting policies. Please refer to Note 5 for highly complex and significant assumptions and estimates made in relation to the consolidated financial report.

(III) Basis of consolidation

1. Basis of preparation for consolidated financial report

Basis of preparation for this consolidated financial report is identical to the 2021 consolidated financial report.

2. Subsidiaries included in the consolidated financial report:

<u>Name of investor</u>	<u>Name of subsidiary</u>	<u>Business activities</u>	<u>Shareholding percentage</u>			<u>Description</u>
			<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>	
The Company	ONYX HEALTHCARE USA, Inc. (OHU)	Sale of medical computers and peripherals	100	100	100	
The Company	ONYX HEALTHCARE EUROPE B.V. (ONI)	Marketing support and maintenance of medical computers and peripherals	100	100	100	Note 1
The Company	Onyx Healthcare (Shanghai) Inc. (OCI)	Sale of medical computers and peripherals	100	100	100	Note 1
The Company	iHELPER Inc. (iHELPER)	Research, development, and sale of medical robots	46	46	46	Note 1 and Note 2

Note 1: These entities do not meet the definition of material subsidiary, and therefore financial statements dated March 31, 2022 and 2021 were not reviewed by CPAs.

Note 2: The Company holds less than 50% aggregate ownership in the entity, but includes it in the preparation of consolidated financial report as the Company has control over the entity's financial, operational, and personnel decisions.

3. Subsidiaries not included in the consolidated financial report: None.
4. Methods for aligning subsidiaries' accounting periods: None.
5. Significant limitations: None.
6. Subsidiaries with non-controlling owners that are significant to the Group: The Group had non-controlling equity outstanding at \$8,486, \$8,871, and \$9,200 on March 31, 2002,

December 31, 2021, and March 31, 2021, respectively. None of the non-controlling shareholders were significant to the Group.

V. Major sources of uncertainty for significant accounting judgments, estimates and assumptions

There were no significant changes in the current period; please refer to Note 5 of the 2021 consolidated financial report.

VI. Notes to major accounts

(I) Cash and cash equivalents

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
Petty cash	\$ 323	\$ 263	\$ 277
Check and current deposit	457,206	182,630	352,123
Time deposit	-	-	40,000
	<u>\$ 457,529</u>	<u>\$ 182,893</u>	<u>\$ 392,400</u>

1. All financial institutions that the Group deals with are of strong credit background. The Group also diversifies credit risk by dealing with multiple financial institutions at the same time and therefore is unlikely to suffer from the default of a financial institution.
2. Cash and cash equivalents that have been placed as collateral for forward exchange contracts are presented as other financial assets (under other current assets). Please see Note 8 for details.

(II) Financial assets at fair value through profit or loss

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
Current portion:			
Financial assets mandatory to be carried at fair value through profit or loss			
TWSE/TPEX listed shares	\$ 9,873	\$ 9,873	\$ 6,250
Valuation adjustment	(1,604)	252	(925)
	<u>\$ 8,269</u>	<u>\$ 10,125</u>	<u>\$ 5,325</u>
Non-current portion:			
Financial assets mandatory to be carried at fair value through profit or loss			
Not listed on TWSE/TPEX or the Emerging Stock Market board	\$ 30,000	\$ 30,000	\$ 30,000
Valuation adjustment	2,197	6,406	12,364
	<u>\$ 32,197</u>	<u>\$ 36,406</u>	<u>\$ 42,364</u>



1. Details of gains or losses on financial assets at fair value through profit or loss:

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Financial assets mandatory to be carried at fair value through profit or loss		
Equity instrument	<u>(\$ 6,065)</u>	<u>\$ 3,916</u>

2. None of the Group's financial assets at fair value through profit or loss was placed as collateral.

3. For information relating to the credit risk of financial assets carried at fair value through profit or loss, please refer to Note 12(2).

(III) Accounts receivable

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
Accounts receivable	\$ 252,512	\$ 219,671	\$ 120,176
Less: loss provisions	<u>( 16,807)</u>	<u>( 16,828)</u>	<u>( 15,703)</u>
	<u>\$ 235,705</u>	<u>\$ 202,843</u>	<u>\$ 104,473</u>

1. Accounts receivable (including related parties) aging analysis:

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
Current	\$ 206,623	\$ 176,777	\$ 96,741
Overdue within 30 days	35,330	27,029	6,166
Overdue 31 - 60 days	165	1,846	2,807
Overdue 61 - 90 days	-	76	318
Overdue 91 - 120 days	-	-	2
Overdue more than 121 days	<u>16,499</u>	<u>16,616</u>	<u>15,213</u>
	<u>\$ 258,617</u>	<u>\$ 222,344</u>	<u>\$ 121,247</u>

The above aging analysis has been prepared based on the number of days overdue.

2. Balances of accounts receivable (including related parties) as of March 31, 2022, December 31, 2021, and March 31, 2021 had arisen entirely from contractual arrangements with customers. Balances of contractual proceeds receivable from customers (including related parties) and loss provisions as of January 1, 2021 were \$168,804 and \$16,040, respectively.

3. In the absence of collaterals and other credit enhancements, maximum credit risk exposure associated with the Group's accounts receivable (including related parties) as of March 31, 2022, December 31, 2021, and March 31, 2021 amounted to \$241,810, \$205,516, and \$105,544, respectively.

4. The Group held no collateral on accounts receivable (including related parties).
5. For credit risk information on accounts receivable (including related parties), please refer to Note 12(2).

(IV) Inventory

	<u>March 31, 2022</u>		
	<u>Cost</u>	<u>Allowance for obsolescence and devaluation loss</u>	<u>Book value</u>
Raw materials	\$ 153,612	(\$ 16,312)	\$ 137,300
Work-in-progress	41,732	( 327)	41,405
Semi-finished goods	79,360	( 10,032)	69,328
Finished goods	55,393	( 21,768)	33,625
	<u>\$ 330,097</u>	<u>(\$ 48,439)</u>	<u>\$ 281,658</u>

	<u>December 31, 2021</u>		
	<u>Cost</u>	<u>Allowance for obsolescence and devaluation loss</u>	<u>Book value</u>
Raw materials	\$ 139,530	(\$ 12,885)	\$ 126,645
Work-in-progress	37,966	( 652)	37,314
Semi-finished goods	76,354	( 9,366)	66,988
Finished goods	53,937	( 18,970)	34,967
Inventory in transit	5,305	-	5,305
	<u>\$ 313,092</u>	<u>(\$ 41,873)</u>	<u>\$ 271,219</u>

	<u>March 31, 2021</u>		
	<u>Cost</u>	<u>Allowance for obsolescence and devaluation loss</u>	<u>Book value</u>
Raw materials	\$ 93,949	(\$ 9,184)	\$ 84,765
Work-in-progress	23,569	( 109)	23,460
Semi-finished goods	50,133	( 7,874)	42,259
Finished goods	52,041	( 16,444)	35,597
Inventory in transit	1,791	-	1,791
	<u>\$ 221,483</u>	<u>(\$ 33,611)</u>	<u>\$ 187,872</u>

Cost of inventory recognized as expenses or losses in the current period:

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Cost of inventory sold	\$ 288,502	\$ 183,456
Obsolescence and devaluation loss	5,951	3,162
Service and warranty cost	5,216	3,551
Impairment loss	<u>-</u>	<u>36</u>
	<u>\$ 299,669</u>	<u>\$ 190,205</u>

(V)Financial assets at fair value through other comprehensive income

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
Non-current portion:			
Equity instrument			
Not listed on TWSE/TPEX or the Emerging Stock Market board	\$ 69,334	\$ 69,334	\$ 39,334
Valuation adjustment	<u>( 38,528)</u>	<u>( 36,953)</u>	<u>( 36,953)</u>
	<u>\$ 30,806</u>	<u>\$ 32,381</u>	<u>\$ 2,381</u>

1. The Group has chosen to classify shares of MELTEN CONNECTED HEALTHCARE INC. and ProtectLife International Biomedical Inc., both of which are strategic investments, as financial assets at fair value through other comprehensive income. Fair values of these investments were reported at \$30,806, \$32,381, and \$2,381 as of March 31, 2022, December 31, 2021, and March 31, 2021.
2. The amounts of fair value changes recognized through comprehensive income for financial assets at fair value through other comprehensive income were (\$1,575) and \$0 for the periods January 1 to March 31, 2022 and 2021, respectively.
3. None of the Group's financial assets at fair value through other comprehensive income was placed as collateral.
4. For information relating to the credit risk of financial assets carried at fair value through other comprehensive income, please refer to Note 12(2).

(VI) Equity-accounted investments

<u>Name of associated company</u>	<u>March 31, 2022</u>		<u>December 31, 2021</u>	
	<u>Shareholding %</u>	<u>Amount presented</u>	<u>Shareholding %</u>	<u>Amount presented</u>
Winmate Inc. (Winmate)(Note)	13.83%	<u>\$ 575,109</u>	13.85%	<u>\$ 561,275</u>

<u>Name of associated company</u>	<u>March 31, 2021</u>	
	<u>Shareholding %</u>	<u>Amount presented</u>
Winmate Inc. (Winmate)(Note)	13.61%	<u>\$ 549,534</u>

Note: Although the Group held less than 20% of voting shares in Winmate, it did undertake directorship in Winmate and therefore accounted for the entity using the equity method for exercising significant influence.

1. Summary financial information of significant associated companies:

Balance sheet

	<u>Winmate</u>		
	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
Current assets	\$ 2,241,844	\$ 2,320,961	\$ 2,241,410
Non-current assets	1,231,700	1,208,922	1,044,210
Current liabilities	( 1,064,210)	( 740,940)	( 491,251)
Non-current liabilities	( 17,707)	( 501,456)	( 496,132)
Total net assets	<u>\$ 2,391,627</u>	<u>\$ 2,287,487</u>	<u>\$ 2,298,237</u>
As a percentage of net assets across associated companies	\$ 332,753	\$ 318,919	\$ 312,790
Goodwill	<u>242,356</u>	<u>242,356</u>	<u>236,744</u>
Book value of associated company	<u>\$ 575,109</u>	<u>\$ 561,275</u>	<u>\$ 549,534</u>

Statement of comprehensive income

	<u>Winmate</u>	
	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Income	<u>\$ 587,714</u>	<u>\$ 584,698</u>
Current net income	\$ 86,337	\$ 81,844
Other comprehensive income (net, after-tax)	<u>14,317</u>	<u>( 45)</u>
Total comprehensive income for the current period	<u>\$ 100,654</u>	<u>\$ 81,799</u>

2. Fair value of associated companies that are openly quoted:

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
Winmate	<u>\$ 792,235</u>	<u>\$ 787,214</u>	<u>\$ 778,191</u>

(VII) Property, plant and equipment

2022

	<u>Machinery</u>	<u>Office equipment</u>	<u>Lease improvements</u>	<u>Other equipment</u>	<u>Construction in progress and equipment pending inspection</u>	<u>Total</u>
January 1						
Cost	\$ 17,980	\$ 9,547	\$ 20,697	\$ 78,525	\$ -	\$ 126,749
Accumulated depreciation	( 14,281)	( 7,946)	( 15,012)	( 65,189)	-	( 102,428)
	<u>\$ 3,699</u>	<u>\$ 1,601</u>	<u>\$ 5,685</u>	<u>\$ 13,336</u>	<u>\$ -</u>	<u>\$ 24,321</u>
January 1	\$ 3,699	\$ 1,601	\$ 5,685	\$ 13,336	\$ -	\$ 24,321
Addition	-	821	-	143	1,300	2,264
Depreciation	( 513)	( 195)	( 1,244)	( 2,259)	-	( 4,211)
Net exchange difference	-	38	-	45	-	83
March 31	<u>\$ 3,186</u>	<u>\$ 2,265</u>	<u>\$ 4,441</u>	<u>\$ 11,265</u>	<u>\$ 1,300</u>	<u>\$ 22,457</u>
March 31						
Cost	\$ 17,980	\$ 10,567	\$ 20,697	\$ 78,781	\$ 1,300	\$ 129,325
Accumulated depreciation	( 14,794)	( 8,302)	( 16,256)	( 67,516)	-	( 106,868)
	<u>\$ 3,186</u>	<u>\$ 2,265</u>	<u>\$ 4,441</u>	<u>\$ 11,265</u>	<u>\$ 1,300</u>	<u>\$ 22,457</u>

2021

	<u>Machinery</u>	<u>Office equipment</u>	<u>Lease improvements</u>	<u>Other equipment</u>	<u>Construction in progress and equipment pending inspection</u>	<u>Total</u>
January 1						
Cost	\$ 17,380	\$ 8,781	\$ 15,187	\$ 66,643	\$ 4,105	\$ 112,096
Accumulated depreciation	( 12,290)	( 7,569)	( 13,251)	( 58,546)	-	( 91,656)
	<u>\$ 5,090</u>	<u>\$ 1,212</u>	<u>\$ 1,936</u>	<u>\$ 8,097</u>	<u>\$ 4,105</u>	<u>\$ 20,440</u>
January 1	\$ 5,090	\$ 1,212	\$ 1,936	\$ 8,097	\$ 4,105	\$ 20,440
Addition	315	891	4,402	7,717	586	13,911
Transfer	-	-	3,007	-	( 3,007)	-
Depreciation	( 482)	( 206)	( 409)	( 1,258)	-	( 2,355)
Net exchange difference	-	( 11)	-	( 14)	-	( 25)
March 31	<u>\$ 4,923</u>	<u>\$ 1,886</u>	<u>\$ 8,936</u>	<u>\$ 14,542</u>	<u>\$ 1,684</u>	<u>\$ 31,971</u>
March 31						
Cost	\$ 17,695	\$ 9,576	\$ 22,596	\$ 74,336	\$ 1,684	\$ 125,887
Accumulated depreciation	( 12,772)	( 7,690)	( 13,660)	( 59,794)	-	( 93,916)
	<u>\$ 4,923</u>	<u>\$ 1,886</u>	<u>\$ 8,936</u>	<u>\$ 14,542</u>	<u>\$ 1,684</u>	<u>\$ 31,971</u>

Major components of property, plant, and equipment held by the Group, and useful lives:

<u>Item</u>	<u>Major component</u>	<u>Useful life</u>
Machinery	Oscilloscope, suspensory burn-in equipment, and automated streamline workstation	3 years
Office equipment	Server and host	3 years
Lease improvements	Plant expansion and revovation works	2 years
Other equipment	Front and back cover mold, repair mold, and sizing mold	2-5 years

1. All property, plant, and equipment mentioned above are self-occupied.
2. No borrowing cost was capitalized into the Group's property, plant, and equipment.
3. None of the Group's property, plant, and equipment was placed as collateral.
4. The Group signed a contract to purchase real estate property located in Xindian District for a price of \$280,077 (tax-inclusive) on March 26, 2021. By March 31, 2021, the Group had paid a sum of \$28,008 (tax-inclusive), and given that the land and buildings were still undergoing ownership transfer, proceeds paid for the first phase of the prepayment contract have been presented as other non-current assets. The remaining proceeds will be paid in May 2022 after ownership transfer is completed.

(VIII)Leases - as a lessee

1. The Group leases buildings, transport equipment, and office equipment; the duration of the lease agreements usually ranges from 1 to 20 years. Lease contracts were individually negotiated and drafted with different terms and conditions with no additional restriction, except that the leased assets can not be placed as collateral.
2. Lease tenors for buildings and transport equipment do not exceed 12 months, whereas leases for office equipment are treated as low-value leases.
3. Book value of right-of-use assets and recognized amounts of depreciation expense are presented below:

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
	<u>Book value</u>	<u>Book value</u>	<u>Book value</u>
Buildings	\$ 38,087	\$ 41,719	\$ 42,207
Transport equipment	677	864	1,573
Office equipment	1,993	2,100	2,422
	<u>\$ 40,757</u>	<u>\$ 44,683</u>	<u>\$ 46,202</u>



	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
	<u>Depreciation</u>	<u>Depreciation</u>
Buildings	\$ 2,306	\$ 3,157
Transport equipment	202	220
Office equipment	107	120
	<u>\$ 2,615</u>	<u>\$ 3,497</u>

4. Amounts of right-of-use assets added during the periods January 1 to March 31, 2022 and 2021, were \$0 and \$41,062, respectively.

5. Income and expenses relating to lease agreements are presented below:

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
<u>Current income/expense accounts affected</u>		
Interest expense on lease liabilities	\$ 73	\$ 156
Expenses on short-term lease agreements	2,466	1,610
Lease expense of low-value leases	11	11
Loss on lease amendment	-	6

6. Amounts of cash outflow incurred on leases totaled \$4,881 and \$5,207 for the periods January 1 to March 31, 2022 and 2021, respectively.

7. Due to extension of existing lease agreements, right-of-use assets and lease liabilities increased by \$7,963 for the period January 1 to March 31, 2021.

#### (IX) Leases - as a lessor

1. The Group leases out its land and buildings. The current lease tenor is from September 2021 to August 2024. Lease contracts are negotiated individually and involve different terms and conditions. To ensure that lease assets are used for the purpose described, lessees are generally prohibited from sub-leasing, lending, or transferring all or part of the leased asset, or in any other way allowing others to make use of the leased asset. Lessees are also prohibited from transferring leases to others.

2. The Group recognized \$1,733 and \$0 of rental income from operating lease agreements for the periods January 1 to March 31, 2022 and 2021; this amount included no variable lease payment.

3. Maturity analysis for lease payments collectible on operating leases:

	<u>March 31, 2022</u>	<u>December 31, 2021</u>
2022	\$ 5,173	\$ 6,897
2023	6,897	6,897
2024	<u>4,598</u>	<u>4,598</u>
	<u>\$ 16,668</u>	<u>\$ 18,392</u>

4. See Note 7 for details on the lease of assets to related parties.

(X)Investment property

	<u>2022</u>		
	<u>Land</u>	<u>Buildings</u>	<u>Total</u>
January 1			
Cost	\$ 229,660	\$ 48,798	278,458
Accumulated depreciation	<u>-</u>	<u>( 813)</u>	<u>( 813)</u>
	<u>\$ 229,660</u>	<u>\$ 47,985</u>	<u>\$ 277,645</u>
January 1			
Depreciation	\$ 229,660	\$ 47,985	277,645
March 31	<u>-</u>	<u>( 407)</u>	<u>( 407)</u>
	<u>\$ 229,660</u>	<u>\$ 47,578</u>	<u>\$ 277,238</u>
March 31			
Cost	\$ 229,660	\$ 48,798	\$ 278,458
Accumulated depreciation	<u>-</u>	<u>( 1,220)</u>	<u>( 1,220)</u>
	<u>\$ 229,660</u>	<u>\$ 47,578</u>	<u>\$ 277,238</u>

1. The Group signed a contract to purchase real estate property located in Xindian District for a price of \$280,077 (tax-inclusive) on March 26, 2021, and ownership transfer was completed in May 2021. The Company previously presented the asset under property, plant, and equipment due to its initial intention to occupy the property; however, relocation and construction activities were disrupted due to COVID-19 control measures, and it was inconvenient to have customers certify the plant relocation on-site during this time. After taking into account the above concerns, a decision was made to postpone plant relocation and lease the plant to a related party in September 2021. For this reason, the asset was reclassified into an investment property.

2. Rent income and direct expenses associated with investment property:

	<u>January 1 to March 31, 2022</u>
Rent income from investment property	<u>\$ 1,733</u>
Direct expenses incurred in relation to current rent income generated from investment property	<u>\$ 407</u>

3. Fair value of the Group's investment properties was reported at \$280,333 as of March 31, 2022 and December 31, 2021 based on the valuation result produced by an independent valuer. The valuation used a combination of the comparative approach and the income approach, which involved level 3 fair value inputs. Main assumptions of the valuation are as follows:

	<u>March 31, 2022</u>	<u>December 31, 2021</u>
Income capitalization rate	1.8%	1.8%

4. See Note 8 for details of investment property pledged as collateral.

(XI) Short-term loans

<u>Nature of loan</u>	<u>March 31, 2022</u>	<u>Interest rate range</u>	<u>Collateral</u>
Bank borrowings			
Unsecured loan	<u>\$ 105,000</u>	1.08%~1.10%	None
<u>Nature of loan</u>	<u>December 31, 2021</u>	<u>Interest rate range</u>	<u>Collateral</u>
Bank borrowings			
Unsecured loan	<u>\$ 105,000</u>	1.08%~1.10%	None

1. None as of March 31, 2021.

2. \$324 of interest expense was recognized in profit or loss for the period January 1 to March 31, 2022.

(XII) Financial liabilities at fair value through profit or loss

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
Current portion:			
Financial liabilities held for trading			
Derivatives - currency forwards	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 116</u>

1. Details of gains (losses) on financial liabilities at fair value through profit or loss:

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Financial liabilities held for trading		
Derivatives	<u>\$ -</u>	<u>(\$ 116)</u>

2. Explanation to derivative liabilities and contracts that do not conform with hedge accounting:

	<u>March 31, 2021</u>	
<u>Derivative financial liabilities</u>	<u>Contract sum</u>	<u>Contract duration</u>
Current portion:	<u>(Notional principal)</u>	
Forward exchange contract - long NTD, short USD US\$	200,000	March 8, 2021 to April 7, 2021
Forward exchange contract - long NTD, short USD US\$	200,000	March 19, 2021 to April 16, 2021

3. The Group had entered into the above forward exchange contracts to take a short position on a particular foreign currency. They were intended to hedge exchange rate risks associated with export sales but no hedge accounting treatment was applied.

(XIII) Other payables

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
Employee and director remuneration payable	\$ 26,214	\$ 21,552	\$ 26,458
Salary and bonus payable	22,376	29,279	20,911
Equipment purchase payable	150	1,726	9,711
Other payables	<u>14,884</u>	<u>21,197</u>	<u>23,397</u>
	<u>\$ 63,624</u>	<u>\$ 73,754</u>	<u>\$ 80,477</u>

(XIV) Long-term loans

<u>Nature of loan</u>	<u>Loan tenor and repayment method</u>	<u>Interest rate range</u>	<u>Collateral</u>	<u>March 31, 2022</u>
Long-term bank borrowings				
Secured borrowings	From May 28, 2021 to May 28, 2036; principal and interest repayable on a monthly basis	1.25%	Land and buildings	\$ 163,113
Less: current portion of long-term loan				<u>( 10,591)</u>
				<u>\$ 152,522</u>

<u>Nature of loan</u>	<u>Loan tenor and repayment method</u>	<u>Interest rate range</u>	<u>Collateral</u>	<u>December 31, 2021</u>
Long-term bank borrowings				
Secured borrowings	From May 28, 2021 to May 28, 2036; principal and interest repayable on a monthly basis	1.00%	Land and buildings	\$ 165,787
Less: current portion of long-term loan				( 10,744)
				<u>\$ 155,043</u>

None as of March 31, 2021.

(XV) Pension

1. The Company and domestic subsidiaries have implemented defined contribution policies in accordance with the "Labor Pension Act" that apply to all employees of local nationality. For employees who are subject to the pension scheme introduced under the "Labor Pension Act," the Company and domestic subsidiaries contribute an amount equal to 6% of employees' monthly salary to their individual accounts held with the Bureau of Labor Insurance on a monthly basis. Upon retirement, employees are paid the balance of their pension account plus cumulative gains either in monthly installments or in one lump sum.
2. OHU currently implements a company-funded personal pension program. Every employee who voluntarily participates in the program may have pension contributions shared between OHU and the employee. OHU makes contributions at 3% of gross salary, up to the amount in employee's self contribution.
3. OCI is required under the retirement insurance system of The People's Republic of China to pay monthly retirement premiums at a certain percentage of gross salary for local employees. Employees' pension funds are collectively managed by the local government. OCI has no further obligations other than making monthly contributions.
4. ONI makes pension contributions according to local regulations.
5. Total pension costs recognized under the above policies amounted to \$1,463 and \$1,552 for the periods January 1 to March 31, 2022 and 2021.

(XVI) Liability reserves

	<u>2022</u>	<u>2021</u>
	<u>Warranty</u>	<u>Warranty</u>
January 1	\$ 8,271	\$ 8,614
Increase of liability reserves in the current period	2,801	1,964
Liability reserves used and reversed in the current period	( 1,939)	( 2,218)
March 31	<u>\$ 9,133</u>	<u>\$ 8,360</u>

Analysis of liability reserves:

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
Current	\$ <u>6,795</u>	\$ <u>6,272</u>	\$ <u>6,406</u>
Non-current	\$ <u>2,338</u>	\$ <u>1,999</u>	\$ <u>1,954</u>

Warranty reserves are related to the sale of medical computers; the amount in which is estimated based on historical warranty information of the product concerned.

(XVII) Share-based payment

- The Group had the following share-based payment arrangements for the periods January 1 to March 31, 2022 and 2021:

<u>Type of agreement</u>	<u>Grant date</u>	<u>Quantity granted (thousand shares)</u>	<u>Contract duration</u>	<u>Vesting condition</u>
Employee warrant program	August 6, 2020	1,000	5 years	2-4 years of service
Cash issue retain for subscription by employees	January 25, 2022	418	Not applicable	Immediately vested

The above share-based payment arrangement is settled with equity.

- Details of the above share-based payment arrangements:

	<u>2022</u>	<u>Weighted average exercise price (NTD)</u>	<u>2021</u>	<u>Weighted average exercise price (NTD)</u>
	<u>Quantity of warrants (thousands)</u>		<u>Quantity of warrants (thousands)</u>	
Opening balance (January 1) of outstanding warrants	1,000	\$ 121.50	1,000	\$ 139.50
Warrants granted in the current period	-	-	-	-
Closing balance (March 31) of outstanding warrants	<u>1,000</u>	119.70	<u>1,000</u>	139.50
Closing balance (March 31) of exercisable warrants	<u>-</u>		<u>-</u>	

3. Maturity date and exercise price of warrants outstanding as of the balance sheet date:

			<u>March 31, 2022</u>	
<u>Type of agreement</u>	<u>Issuance date</u>	<u>Maturity date</u>	<u>Shares (thousand shares)</u>	<u>Exercise price (NTD)</u>
Employee warrant program	August 6, 2020	August 6, 2025	1,000	\$ 119.70
			<u>December 31, 2021</u>	
<u>Type of agreement</u>	<u>Issuance date</u>	<u>Maturity date</u>	<u>Shares (thousand shares)</u>	<u>Exercise price (NTD)</u>
Employee warrant program	August 6, 2020	August 6, 2025	1,000	\$ 121.50
			<u>March 31, 2021</u>	
<u>Type of agreement</u>	<u>Issuance date</u>	<u>Maturity date</u>	<u>Shares (thousand shares)</u>	<u>Exercise price (NTD)</u>
Employee warrant program	August 6, 2020	August 6, 2025	1,000	\$ 139.50

4. The Group uses the Black-Scholes options pricing model to estimate the fair value of warrants allocated for share-based payment and the fair value of cash issues retained for subscription by employees. Information on relevant parameters is presented below:

<u>Type of agreement</u>	<u>Grant date</u>	<u>Share price</u>	<u>Exercise price expectations (NTD)</u>	<u>Volatility</u>	<u>Expected duration</u>	<u>Risk-free rate</u>	<u>Fair value per unit (NTD)</u>
Employee warrant program	August 6, 2020	\$ 139.50	\$ 139.50	32.26%	3.88 years	0.29%	\$ 35.39
Cash issue retain for subscription by 2022 employees	January 25,	107.50	88.00	18.32%	0.16 years	0.34%	19.5567

5. Expenses incurred on share-based payments are as follows:

	<u>January 1 to March 31, 2022</u>		<u>January 1 to March 31, 2021</u>	
Cash issue retain for subscription by employees	\$	8,174	\$	-
Employee warrants		2,197		2,904
	\$	10,371	\$	2,904

(XVIII) Share capital

1. Having accumulated the required number of electronic votes, a resolution was passed during the shareholder meeting held in May 2021 to capitalize \$27,510 of earnings and issue 2,751,000 new shares. Registration for the above capital increase was completed in September 2021.

- The Company had \$500,000 of authorized capital (including 6,000,000 shares reserved for issuance of employee warrant) as per Articles of Incorporation and \$302,612 of paid-up capital issued in 30,261,000 shares at a face value of NT\$10 per share as of March 31, 2022.

Reconciliation between the opening and closing number of outstanding common shares (in thousand shares) in 2022 and 2021 is explained below:

	<u>2022</u>	<u>2021</u>
January 1 (i.e. March 31)	<u>30,261</u>	<u>27,510</u>

- The board of directors passed a resolution on August 7, 2019 to issue employee warrants and later resolved on December 23, 2019 to amend the issuance policy. A total of 1,000 units of the warrant were issued, and each warrant is vested with the right to subscribe 1,000 shares. 1,000,000 new common shares will have to be issued when the warrants are exercised. The subscription price per share will be determined according to policy. The warrants mentioned above were issued on August 6, 2020; please see Note 6(17) for details.
- The board of directors passed a resolution to issue 3,000,000 common shares for cash during the meeting held on December 17, 2021. The cash issue was effected after it was reported to the authority on January 13, 2022. The board of directors passed a resolution on January 25, 2022 to set the issuance price of the above cash issue at NT\$88 per share. The entire proceeds of \$264,000 were collected by April 1, 2022; the Company designated April 1, 2022 as the baseline date for cash issue and completed change of capital registration later on April 14, 2022.

(XIX)Capital reserves

Pursuant to The Company Act, the amount in premiums received on shares issued above the face value plus any capital reserves arising from gifts received may be used to reimburse previous losses. If the Company has not accumulated losses, this amount may be distributed to shareholders in cash or new shares based on shareholders' exiting ownership percentage. Furthermore, according to the Securities and Exchange Act, the amount in capital reserves capitalized into share capital is capped at 10% of paid-up capital per year. The Company may not utilize capital reserves to offset losses when there is still a positive balance in the earning reserves.



	<u>2022</u>		
	<u>Share premium</u>	<u>Employee warrants</u>	<u>Total</u>
January 1	\$ 446,346	\$ 16,327	\$ 462,673
Cash issue retain for subscription by employees	-	8,174	8,174
Employee warrants	-	<u>2,197</u>	<u>2,197</u>
March 31	<u>\$ 446,346</u>	<u>\$ 26,698</u>	<u>\$ 473,044</u>

	<u>2021</u>		
	<u>Share premium</u>	<u>Employee warrants</u>	<u>Total</u>
January 1	\$ 473,856	\$ 4,710	\$ 478,566
Employee warrants	-	<u>2,904</u>	<u>2,904</u>
March 31	<u>\$ 473,856</u>	<u>\$ 7,614</u>	<u>\$ 481,470</u>

(XX)Retained earnings

1. According to the Articles of Incorporation, annual net income concluded by the Company is first subject to reimbursement of previous losses (including adjustment to unappropriated earnings) followed by a 10% provision for legal reserve. However, no further provision is needed when legal reserve has accumulated to an amount equal to the Company's paid-up capital. Any surpluses remaining shall be subject to provision or reversal of special reserve as laws or the authority may require. The residual balance can then be added to unappropriated earnings (including adjustment to unappropriated earnings) carried from previous years and distributed as dividends to shareholders, subject to board of directors' proposal and shareholder meeting resolution. The amount of dividends paid to shareholders must not be less than 5% of total distributable earnings. Cash dividends must not be less than 10% of the sum of cash and stock dividends for the current year. However, cash dividends amounting to less than NT\$0.1 per share are to be paid in stock dividends instead.

The Company adopts a residual dividend policy that takes into consideration current and future investment prospects, capital requirements, local and foreign competition, capital budget, shareholders' interest, balanced dividend, long-term financial plans and related factors.

2. The legal reserve may not be used for purposes other than reimbursing previous losses or distributing proportionally back to existing shareholders in the form of cash or new shares. Only the amount of reserve that exceeds paid-up capital by 25% may be distributed in the form of cash or new shares.
3. When distributing earnings, the Company is bound by laws to make provision for special reserves equal to the debit balance of other equity items as of the current balance sheet

date before proceeding. If the debit balance of other equity items is reversed on a later date, the amount reversed can be added to available earnings for distribution.

4. The board of directors passed its 2021 earnings appropriation proposal on April 14, 2022, whereas the 2020 earnings appropriation proposal was resolved by shareholders on May 22, 2021 after accumulating the required number of electronic votes. Details are as follows:

	<u>2021</u>		<u>2020</u>	
	<u>Amount</u>	<u>Dividends per share (NTD)</u>	<u>Amount</u>	<u>Dividends per share (NTD)</u>
Legal reserves	\$ 12,755		\$ 16,707	
Special reserves	4,903		4,730	
Cash dividends	99,784	\$ 3.0	123,796	\$ 4.5
Stock dividends	-	-	27,510	1.0
	<u>\$ 117,442</u>		<u>\$ 172,743</u>	

(1) A resolution was passed during the board of directors meeting held on April 14, 2022 to issue additional common shares at a premium above face value against the capitalization of \$33,261 in capital reserves. This is equivalent to NT\$1 of stock dividend per share.

(2) A resolution was passed after accumulating the required number of electronic votes during the shareholder meeting held on May 22, 2021 to issue additional common shares at a premium above face value against the capitalization of \$27,510 in capital reserves. This is equivalent to NT\$1 of stock dividend per share.

Appropriation of 2020 earnings, as explained above, was indifferent from the proposals raised by the board of directors. The 2021 earnings appropriation proposal had yet to be resolved by shareholders as of May 3, 2022, therefore the consolidated financial statements do not reflect the amount of dividends payable.

(XXI)Operating revenues

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Revenue from contracts with customers	<u>\$ 419,208</u>	<u>\$ 273,277</u>

## 1. Breakdown of revenue from contracts with customers

The Group recognizes income when merchandise is transferred or when service is rendered, which may take place progressively over time or occur at a specific time.

Income can be distinguished by main product lines and geographic areas as follows:

<u>January 1 to March 31, 2022</u>	<u>Medical computers</u>			<u>Services and warranty</u>			<u>Total</u>
	<u>Taiwan</u>	<u>USA</u>	<u>Others</u>	<u>Taiwan</u>	<u>USA</u>	<u>Others</u>	
Revenue from contracts with external customers	<u>\$187,659</u>	<u>\$202,387</u>	<u>\$18,422</u>	<u>\$6,866</u>	<u>\$3,810</u>	<u>\$ 64</u>	<u>\$419,208</u>
Timing of revenue recognition							
Revenues recognized at a specific time	\$187,659	\$202,387	\$18,422	\$ -	\$ -	\$ -	\$408,468
Revenues recognized progressively over time	-	-	-	6,866	3,810	64	10,740
	<u>\$187,659</u>	<u>\$202,387</u>	<u>\$18,422</u>	<u>\$6,866</u>	<u>\$3,810</u>	<u>\$ 64</u>	<u>\$419,208</u>

<u>January 1 to March 31, 2021</u>	<u>Medical computers</u>			<u>Services and warranty</u>		<u>Total</u>
	<u>Taiwan</u>	<u>USA</u>	<u>Others</u>	<u>Taiwan</u>	<u>USA</u>	
Revenue from contracts with external customers	<u>\$ 151,600</u>	<u>\$ 106,415</u>	<u>\$ 7,923</u>	<u>\$ 6,661</u>	<u>\$ 678</u>	<u>\$ 273,277</u>
Timing of revenue recognition						
Revenues recognized at a specific time	\$ 151,600	\$ 106,415	\$ 7,923	\$ -	\$ -	\$ 265,938
Revenues recognized progressively over time	-	-	-	6,661	678	7,339
	<u>\$ 151,600</u>	<u>\$ 106,415</u>	<u>\$ 7,923</u>	<u>\$ 6,661</u>	<u>\$ 678</u>	<u>\$ 273,277</u>

## 2. Contractual liabilities

(1) Contractual liabilities associated with revenue from contracts with customers are as follows:

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>	<u>January 1, 2021</u>
Contractual liabilities - current:				
Service and sales contract	\$ 75,141	\$ 64,568	\$ 36,879	\$ 40,482
Warranty contract	10,512	11,187	13,733	14,523
Contractual liabilities - non-current:				
Service and sales contract	51,070	26,024	31,976	31,995
Warranty contract	15,059	16,114	18,890	21,077
	<u>\$ 151,782</u>	<u>\$ 117,893</u>	<u>\$ 101,478</u>	<u>\$ 108,077</u>

(2) Amount in opening contractual liabilities recognized as current income

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Amount in opening contractual liabilities recognized as current income		
Service and sales contract	\$ 17,879	\$ 14,203
Warranty contract	<u>3,049</u>	<u>3,843</u>
	<u>\$ 20,928</u>	<u>\$ 18,046</u>

(3) Long-term contracts not yet fulfilled

The Group had long-term contracts with customers that were unfulfilled (or not fully fulfilled) as of March 31, 2022, December 31, 2021, and March 31, 2021, which had allocated prices of \$151,782, \$117,893, and \$101,478, respectively. The management expects to recognize \$85,653, \$75,755, and \$50,612 of revenues from allocated prices of unfulfilled performance obligations as of March 31, 2022, December 31, 2021, and March 31, 2021, in the following year, whereas the remaining contract prices are expected to be recognized as income over 2 to 8 years. The above amounts do not include constraining estimates of variable consideration.

(XXII) Other income

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Dividend income	\$ 3,367	\$ -
Rental income	1,733	-
Other income	<u>1,618</u>	<u>1,305</u>
	<u>\$ 6,718</u>	<u>\$ 1,305</u>

(XXIII) Other gains and losses

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Net gain (loss) on currency exchange	\$ 7,096	(\$ 2,081)
(Loss) gain on financial assets or liabilities at fair value through profit or loss	( 6,065)	3,800
Depreciation of investment property	( 407)	-
Loss on lease amendment	<u>-</u>	<u>( 6)</u>
	<u>\$ 624</u>	<u>\$ 1,713</u>

(XXIV) Additional information on the nature of costs and expenses

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Employee benefit expenses	\$ 76,173	\$ 61,189
Depreciation on property, plant, and equipment	4,211	2,355
Depreciation on right-of-use assets	2,615	3,497
Amortization	483	419
	<u>\$ 83,482</u>	<u>\$ 67,460</u>

(XXV) Employee benefit expenses

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Salary expenses	\$ 68,498	\$ 53,773
Labor/health insurance premium	5,552	5,281
Pension expense	1,463	1,552
Other personnel expenses	660	583
	<u>\$ 76,173</u>	<u>\$ 61,189</u>

1. According to the Articles of Incorporation, any profits remaining after reimbursing cumulative losses in a given year shall be subject to employee remuneration of no less than 5% and director remuneration of no higher than 3%.
2. The Company had estimated employee remuneration at \$4,062 and \$1,336, and director remuneration at \$600 and \$600, for the periods January 1 to March 31, 2022 to 2021, respectively. All above amounts were presented as salary expenses for the respective years.

Amounts for the period January 1 to March 31, 2022 were estimated based on current year's profits to date and the percentages outlined in the Articles of Incorporation.

The board of directors had resolved to pay 2021 employee remuneration and director remuneration at \$11,329 and \$2,400, respectively; both figures were consistent with the amounts previously recognized in the 2021 financial report and were to be paid in cash. Payment had yet to be completed as of May 3, 2022.

Details of employees' and directors' remuneration passed by the Company's board of directors can be found on the Market Observation Post System.

(XXVI) Income tax

1. Income tax expenses
  - (1) Composition of income tax expense:

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Current income tax:		
Income tax on current profit	\$ 8,141	\$ 1,382
Underestimation of income tax expenses in previous years	<u>866</u>	<u>-</u>
Total current income tax	9,007	1,382
Deferred income tax:		
Occurrence and reversal of temporary difference	<u>487</u>	<u>(357)</u>
Income tax expense	<u>\$ 9,494</u>	<u>\$ 1,025</u>

(2) Income tax on other comprehensive income:

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Translation differences from foreign operations	<u>\$ 807</u>	<u>(\$ 125)</u>

- OCI, one of the consolidated entities, is incorporated in the People's Republic of China as a production-oriented foreign enterprise and is governed by the Enterprise Income Tax Law of the People's Republic of China.
- Profit-seeking enterprise business income tax returns of the Company and iHELPER have been certified by the tax authority up to 2020.

(XXVII) EPS

	<u>January 1 to March 31, 2022</u>		
	<u>Amount after tax</u>	<u>Weighted average outstanding shares (thousand shares)</u>	<u>Earnings per share (NTD)</u>
<u>Basic earnings per share</u>			
Current net income attributable to common shareholders of parent company	<u>\$ 41,943</u>	<u>30,261</u>	<u>\$ 1.39</u>
<u>Diluted earnings per share</u>			
Current net income attributable to common shareholders of parent company	\$ 41,943	30,261	
Dilutive effect of potential common shares			
Employee remuneration	<u>-</u>	<u>103</u>	
Current net income attributable to common shareholders of parent company plus the effect of potential common shares	<u>\$ 41,943</u>	<u>30,364</u>	<u>\$ 1.38</u>

	<u>January 1 to March 31, 2021</u>		
	Amount after tax	Retrospective adjustment to outstanding shares (thousand shares)(Note)	Earnings per share (NTD)
<u>Basic earnings per share</u>			
Current net income attributable to common shareholders of parent company	<u>\$ 17,375</u>	<u>30,261</u>	<u>\$ 0.57</u>
<u>Diluted earnings per share</u>			
Current net income attributable to common shareholders of parent company	\$ 17,375	30,261	
Dilutive effect of potential common shares			
Employee remuneration	<u>-</u>	<u>79</u>	
Current net income attributable to common shareholders of parent company plus the effect of potential common shares	<u>\$ 17,375</u>	<u>30,340</u>	<u>\$ 0.57</u>

Employee warrants issued by the Company had an anti-dilutive in periods January 1 to March 31, 2022 and 2021, and were therefore excluded from the calculation of diluted earnings per share.

Note: The outstanding shares mentioned above have been adjusted retrospectively for the capitalization of unappropriated earnings in 2020.

(XXVIII)Supplementary cash flow information

Investing activities involving partial cash outlay:

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Purchase of property, plant, and equipment	\$ 2,264	\$ 13,911
Plus: equipment proceeds payable at the beginning of the period	1,726	245
Less: Equipment proceeds payable at the end of the period	( 150)	( 9,711)
Cash paid during the current period	\$ 3,840	\$ 4,445

(XXIX)Change of liabilities relating to financing activities

	<u>2022</u>			
	<u>Short-term loans</u>	<u>Long-term loans</u>	<u>Lease liabilities</u>	<u>Total</u>
January 1	\$ 105,000	\$ 165,787	\$ 44,764	\$ 315,551
Repayment of long-term loan	-	( 2,674)	-	( 2,674)
Repayment of lease principal	-	-	( 2,331)	( 2,331)
Effects of exchange rate change	-	-	164	164
Other changes without cash effect	-	-	( 1,378)	( 1,378)
March 31	<u>\$ 105,000</u>	<u>\$ 163,113</u>	<u>\$ 41,219</u>	<u>\$ 309,332</u>
	<u>2021</u>			
	<u>Short-term loans</u>	<u>Long-term loans</u>	<u>Lease liabilities</u>	<u>Total</u>
January 1	\$ -	\$ -	\$ 9,401	\$ 9,401
Repayment of lease principal	-	-	( 3,430)	( 3,430)
Effects of exchange rate change	-	-	( 178)	( 178)
Other changes without cash effect	-	-	40,558	40,558
March 31	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 46,351</u>	<u>\$ 46,351</u>

VII.Related party transactions

(I)Parent company and ultimate controller

The Company (incorporated in the Republic of China) has 50% of its shares controlled by AAEON Technology Inc. AAEON Technology Inc. is the parent company, whereas ASUSTeK Computer Inc. is the ultimate controller of the Company.



(II)Name and relationship of related parties

Name of related party

ASUSTeK Computer Inc.

AAEON Technology Inc.

AAEON Technology (Su Zhou) Inc.

AAEON TECHNOLOGY SINGAPORE  
PTE.LTD.

AAEON ELECTRONICS,INC.

Winmate Inc.

Litemax Electronics Inc.

IBASE Technology Inc.

WT Microelectronics Co., Ltd.

NuVision Technology, Inc.

Morrihan International Corp.

Fu Li Investment Co., Ltd.

Everfocus Electronics Corporation

EverFocus Electronics Corp. (USA)

Kinpo Electronics Inc.

New Era AI Robotics Inc.

MedAlliance Inc.

Relationship with the Group

The Company's ultimate parent company

The Company's parent company

Affiliated subsidiary - with the common ultimate parent

Affiliated subsidiary - with the common ultimate parent

Affiliated subsidiary - with the common ultimate parent

Associated company - investee accounted by the  
Company using the equity method

Other related party - investee accounted by the  
Company's parent using the equity method

Other related party - investee accounted by the  
Company's parent using the equity method

Other related party - investee accounted by the  
Company's affiliated subsidiary using the equity method

Other related party - subsidiary of an investee accounted  
by the Company's affiliated subsidiary using the equity  
method

Other related party - subsidiary of an investee accounted  
by the Company's affiliated subsidiary using the equity  
method

Other related party - the Company's Chairman  
concurrently serves as chairman in the entity

Other related party - the Company's Chairman  
concurrently serves as chairman in the entity

Other related party - the Company's Chairman  
concurrently serves as chairman in the entity's parent

Other related party - iHELPER's chairman serves as  
director for the entity

Other related party - subsidiary of a shareholder that has  
significant influence over iHELPER

Other related party - the Company's Chairman is a 1st-  
degree relative to the chairman of the entity

(III) Major transactions with related parties

1. Operating revenues

	<u>January 1 to March 31,</u> <u>2022</u>	<u>January 1 to March 31,</u> <u>2021</u>
Sales of goods:		
Parent company	\$ 3,835	\$ 103
Affiliated subsidiary of the same group	2,418	991
Associated company	14	5
Other related parties	169	132
	<u>\$ 6,436</u>	<u>\$ 1,231</u>

Selling prices of transactions with related parties were determined between the Group and the related counterparties, and there were no transactions of similar nature available for comparison. Other sales transactions were handled according to normal trade terms (at market price). Sales proceeds were collectible 30-60 days after shipment or 30 days after the current month-end.

2. Purchases

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Purchase of merchandise:		
Parent company		
AAEON Technology Inc.	\$ 67,370	\$ 51,730
Associated company	717	619
Other related parties	3,230	1,250
	<u>\$ 71,317</u>	<u>\$ 53,599</u>

The abovementioned purchases were handled according to normal trade terms (at market price). Payments were made 30 days after delivery or 30-60 days after month-end.

3. Operating costs and expenses

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Parent company	\$ 2,803	\$ 1,667
Affiliated subsidiary of the same group	1,117	1,099
Associated company	8	38
Other related parties	79	633
	<u>\$ 4,007</u>	<u>\$ 3,437</u>

The above operating costs and expenses mainly represent service charges and sundry expenses.

#### 4. Other income

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Other related parties		
EverFocus Electronics Corp. (USA)	\$ <u>1,260</u>	\$ <u>1,276</u>

Other income presented above mainly comprises income from administrative and support services.

#### 5. Rental income (presented as other income)

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Parent company		
AAEON Technology Inc.	\$ <u>1,733</u>	\$ <u>-</u>

Rent between the Group and related parties is negotiated after taking into consideration the market rate of nearby areas. Rent payments are collected on a monthly basis.

#### 6. Related party receivables

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
Accounts receivable:			
Parent company	\$ 3,530	\$ 2,093	\$ 88
Affiliated subsidiary of the same group	2,379	447	845
Associated company	14	-	5
Other related parties	<u>182</u>	<u>133</u>	<u>133</u>
	<u>\$ 6,105</u>	<u>\$ 2,673</u>	<u>\$ 1,071</u>

#### 7. Related party payables

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
Accounts payable:			
Parent company			
AAEON Technology Inc.	\$ 32,362	\$ 31,709	\$ 20,699
Associated company	19	22	297
Other related parties	<u>2,216</u>	<u>942</u>	<u>2,860</u>
	<u>\$ 34,597</u>	<u>\$ 32,673</u>	<u>\$ 23,856</u>

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
Other payables:			
Parent company	\$ 151	\$ 152	\$ 437
Associated company	-	-	3
Other related parties	<u>51</u>	<u>3</u>	<u>56</u>
	<u>\$ 202</u>	<u>\$ 155</u>	<u>\$ 496</u>

#### 8. Leases - as a lessee

##### (1) Acquisition of right-of-use assets

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Affiliated subsidiary of the same group		
AAEON ELECTRONICS, INC.	<u>\$ -</u>	<u>\$ 7,963</u>

Extension of existing lease agreements with affiliated subsidiary in the period January 1 to March 31, 2021 increased right-of-use assets and lease liabilities by \$7,963.

##### (2) Lease liabilities

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
Affiliated subsidiary of the same group			
AAEON ELECTRONICS, INC.			
Current	<u>\$ 3,113</u>	<u>\$ 3,987</u>	<u>\$ 3,952</u>
Non-current	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 3,103</u>

The Group leases office premises from one of its affiliated subsidiaries; the lease tenor began January 2021 and ends December 2022. Amounts paid in relation to the above totaled \$1,032 and \$1,046 for the periods January 1 to March 31, 2022 and 2021.

#### 9. Guarantee deposits received

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
Parent company			
AAEON Technology Inc.	<u>\$ 1,148</u>	<u>\$ 1,148</u>	<u>\$ -</u>

Represents rental deposit.

(IV) Compensation for key management

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Short-term employee benefits	\$ 14,266	\$ 11,016
Retirement benefits	187	154
	<u>\$ 14,453</u>	<u>\$ 11,170</u>

VIII. Pledged assets

The Group had placed the following assets as collaterals:

<u>Assets</u>	<u>Book value</u>			<u>Purpose of security</u>
	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>	
Time deposit (presented as other current assets)	<u>\$ 859</u>	<u>\$ 830</u>	<u>\$ 856</u>	Security for forward exchange contract
Guarantee deposits paid (presented as other current and non-current assets)	<u>\$ 3,402</u>	<u>\$ 3,224</u>	<u>\$ 14,909</u>	Rental deposit for office and warehouse space, and deposit for special projects
Land (presented as investment property)	<u>\$ 229,660</u>	<u>\$ 229,660</u>	<u>\$ -</u>	Long-term loans
Buildings (presented as investment property)	<u>\$ 47,578</u>	<u>\$ 47,985</u>	<u>\$ -</u>	Long-term loans

IX. Major contingent liabilities and unrecognized contractual commitments

(I) Contingencies

None.

(II) Commitments

Please see Note 6(7) for details.

## X. Losses from major disasters

None.

## XI. Major post-balance sheet date events

(I) See Note 6(18)4 for details on the cash issue resolved by the board of directors during the meeting held on December 17, 2021.

(II) Appropriation of 2021 earnings has been proposed and passed by the board of directors during the meeting held on April 14, 2022; please see Note 6(20) for details.

## XII. Others

### (I) Capital management

Objectives of the Group's capital management efforts are to ensure continuity of business activities and maintain the optimal capital structure that minimizes funding costs while maximizing returns for shareholders. To maintain or adjust the capital structure, the Group may revise the amount in dividends paid to shareholders, refund capital back to shareholders, issue new shares, or reduce debts by making more effective use of working capital.

### (II) Financial instruments

#### 1. Types of financial instrument

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
<u>Financial assets</u>			
Financial assets at fair value through profit or loss			
Financial assets mandatory to be carried at fair value through profit or loss	<u>\$ 40,466</u>	<u>\$ 46,531</u>	<u>\$ 47,689</u>
Financial assets at fair value through other comprehensive income			
Voluntarily designated as an investment in an equity instrument	<u>\$ 30,806</u>	<u>\$ 32,381</u>	<u>\$ 2,381</u>
Financial assets carried at cost after amortization			
Cash and cash equivalents	\$ 457,529	\$ 182,893	\$ 392,400
Accounts receivable	235,705	202,843	104,473
Accounts receivable - related parties	6,105	2,673	1,071
Other receivables	3,743	4,564	1,868
Other financial assets (presented as other current assets)	859	830	856
Guarantee deposits paid (presented as other current and non-current assets)	<u>3,402</u>	<u>3,224</u>	<u>14,909</u>
	<u>\$ 707,343</u>	<u>\$ 397,027</u>	<u>\$ 515,577</u>

	<u>March 31, 2022</u>	<u>December 31, 2021</u>	<u>March 31, 2021</u>
Financial liabilities			
Financial liabilities at fair value through profit or loss			
Financial liabilities held for trading	\$ -	\$ -	\$ 116
Financial liabilities carried at cost after amortization			
Short-term loans	\$ 105,000	\$ 105,000	\$ -
Accounts payable	93,315	91,857	69,273
Accounts payable - related parties	34,597	32,673	23,856
Other payables	63,624	73,754	80,477
Long-term loans (including those due within one year)	163,113	165,787	-
Guarantee deposits received	1,148	1,148	-
	<u>\$ 460,797</u>	<u>\$ 470,219</u>	<u>\$ 173,606</u>
Lease liabilities	<u>\$ 41,219</u>	<u>\$ 44,764</u>	<u>\$ 46,351</u>

## 2. Risk management policy

- (1) The Group's day-to-day operations are susceptible to multiple forms of financial risk, including market risks (exchange rate risk, interest rate risk, and price risk), credit risks, and liquidity risks. The Group undertakes forward exchange contracts to eliminate exchange rate risks, thereby minimizing the adverse impact of uncertainties on the Group's financial performance.
- (2) Risk management is performed by the Group's Treasury Department according to board-approved policies. The Treasury Department is responsible for identifying, assessing, and mitigating financial risks, and it achieves this by working closely with other departments within the Group. The board of directors has implemented written principles on risk management practices and outlined policies for specific matters such as exchange rate risk, interest rate risk, credit risk, use of derivative/non-derivative instruments, and investment of residual liquid capital.
- (3) Please see Note 6(12) for more details on the use of derivatives for financial risk mitigation.

## 3. Characteristics and level of significant financial risks

### (1) Market risk

#### Exchange rate risk

- A. The Group is a multinational organization, and transactions undertaken by the Company and subsidiaries in currencies other than the functional currency would give rise to exchange rate risks. USD accounts for the highest exposure of exchange rate risk. Exchange rate risks arise from future commercial transactions and recognized amounts of assets and liabilities.

- B. The management has implemented policies to guide Group affiliates in managing exchange rate risks associated with their functional currencies. All entities are required to hedge exchange rate risks through the Group's Treasury Department. Exchange rate risks are measured by the value of USD transactions that are highly likely to occur. Instruments such as forward exchange are used to mitigate the effect of exchange rate volatility on expected sales revenues.
- C. The Group uses forward exchange contracts to mitigate exchange rate risks but does not adopt hedge accounting treatment. Instead, it presents them as financial assets or liabilities at fair value through profit or loss. Please refer to Note 6(12) for details.
- D. Some of the Group's business activities involve non-functional currencies (the Company and some of its subsidiaries use NTD as the functional currency, while some overseas subsidiaries use USD as the functional currency) and are therefore susceptible to exchange rate fluctuations. Information on foreign currency-denominated assets and liabilities susceptible to significant exchange rate fluctuation is presented below:

	<u>March 31, 2022</u>		Book value
(Foreign currency: functional currency)	<u>Foreign currency (thousand dollars)</u>	<u>Exchange rate</u>	<u>(NTD)</u>
<u>Financial assets</u>			
<u>Monetary items</u>			
USD:NTD	\$ 5,978	28.625	\$ 171,120
<u>Financial liabilities</u>			
<u>Monetary items</u>			
USD:NTD	1,612	28.625	46,144
	<u>December 31, 2021</u>		Book value
(Foreign currency: functional currency)	<u>Foreign currency (thousand dollars)</u>	<u>Exchange rate</u>	<u>(NTD)</u>
<u>Financial assets</u>			
<u>Monetary items</u>			
USD:NTD	\$ 4,628	27.68	\$ 128,103
<u>Financial liabilities</u>			
<u>Monetary items</u>			
USD:NTD	1,239	27.68	34,296



		<u>March 31, 2021</u>		
		<u>Foreign currency (thousand dollars)</u>	<u>Exchange rate</u>	<u>Book value (NTD)</u>
(Foreign currency: functional currency)				
<u>Financial assets</u>				
<u>Monetary items</u>				
USD:NTD	\$	4,319	28.535	\$ 123,243
<u>Financial liabilities</u>				
<u>Monetary items</u>				
USD:NTD		1,221	28.535	34,841

E. Total gain (loss) on exchange (realized and unrealized) recognized by the Group for monetary items susceptible to significant exchange rate fluctuation in the periods January 1 to March 31, 2022 and 2021, amounted to \$7,096 and (\$2,081), respectively.

F. The following is an analysis of risk exposures to various foreign currencies and impacts of significant exchange rate fluctuations:

		<u>January 1 to March 31, 2022</u>		
		<u>Sensitivity analysis</u>		
		<u>Variation</u>	<u>Effect on profit and loss</u>	<u>Effect on other comprehensive income</u>
(Foreign currency: functional currency)				
<u>Financial assets</u>				
<u>Monetary items</u>				
USD:NTD		1%	\$ 1,711	\$ -
<u>Financial liabilities</u>				
<u>Monetary items</u>				
USD:NTD		1%	461	-

<u>January 1 to March 31, 2021</u>			
<u>Sensitivity analysis</u>			
	<u>Variation</u>	<u>Effect on profit and loss</u>	<u>Effect on other comprehensive income</u>
(Foreign currency: functional currency)			
<u>Financial assets</u>			
<u>Monetary items</u>			
USD:NTD	1%	\$ 1,232	\$ -
<u>Financial liabilities</u>			
<u>Monetary items</u>			
USD:NTD	1%	348	-

#### Price risk

- A. Equity instruments held by the Group exposed to price risks have been presented as financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income. For better management of price risks on equity instruments, the Group has implemented concentration limits and diversified its investment portfolio accordingly.
- B. The Group mainly invests in equity instruments issued by local companies. Prices of these equity instruments are affected by the uncertainty associated with the future value of the underlying investment. A 1% rise/fall in the price of equity instruments would increase/decrease gain or loss on equity instruments at fair value through profit or loss, and hence net income, by \$405 and \$477 for the periods January 1 to March 31, 2022 and 2021, respectively, assuming that all other factors remain unchanged. For equity investments that are carried at fair value through other comprehensive income, the above changes would increase/decrease gain or loss on investment by \$308 and \$24, respectively.

#### Cash flow and fair value risk of interest rate

- A. The Group's exposure to interest rate risk arises mainly from short-term and long-term loans borrowed at floating interest rates, which gives rise to the risk of cash flow change due to interest rates. This risk is partially offset by cash and cash equivalents held at a floating interest rate. The Group's floating rate borrowings for the periods January 1 to March 31, 2022 were denominated in NTD.
- B. A 1% rise/fall in the borrowing interest rate would reduce/increase net income by \$536 for the period January 1 to March 31, 2022, assuming that all other factors remain unchanged. These changes are mainly attributed to changes in interest expense on loans borrowed at the floating rate.

(2) Credit risk

- A. Credit risk refers to the possibility of losses suffered by the Group due to its customers or financial instrument counterparties becoming unable to fulfill contractual obligations. These risk events mostly involve the counterparties being unable to settle and pay accounts receivable according to the prescribed terms.
- B. The Group has developed credit risk management practices from a group perspective. According to the Group's internal credit policy, all operating entities are required to perform credit risk management and analysis on every new customer before establishing payment and delivery terms. The Company adopts an internal risk management system that assesses credit quality by considering customers' financial position, previous conduct, and other relevant factors. The board of directors sets individual counterparty risk limits based on internal or external assessments. Uses of credit limit are monitored on a regular basis.
- C. The Group adopts the assumptions stated in IFRS 9 and treats a contract to be in default if payment is overdue for more than 90 days.
- D. The Group has adopted the following assumptions mentioned in IFRS 9 to provide the basis for identifying any significant increase in credit risk of a financial instrument held on hand after initial recognition:  
A financial asset is considered to have exhibited a significant increase in credit risk after initial recognition when contractual payment (according to the terms of the underlying contract) becomes past due for more than 30 days.
- E. The Group distinguishes accounts receivable (including related parties) by customers' characteristics, and adopts a simplified approach along with the use of provision matrix and loss given default to estimate expected credit loss.
- F. Financial assets that are rationally deemed unrecoverable after exhausting collection efforts are charged off. In which case, however, the Group will continue taking legal actions to secure debt entitlement. The Group had no charged-off debt with ongoing collection activities as of March 31, 2022, December 31, 2021, and March 31, 2021.
- G. (1) Customers of good credit background and insured accounts receivable are subject to loss given default of 0.2%. As of March 31, 2022, December 31, 2021, and March 31, 2021, the Company had outstanding accounts receivable of \$199,746, \$159,372, and \$101,392 and had made bad debt provisions of \$399, \$340 and \$203, respectively.
- (2) The Group takes into account multiple considerations, including the Monitoring Indicator published by National Development Council, future prospects, historical and current information etc. to determine loss given default, which is used for estimating loss provisions on accounts receivable

from customers (including related parties) under normal credit conditions. Provision matrix as of March 31, 2022, December 31, 2021, and March 31, 2021 is as follows:

	<u>Current</u>	<u>Overdue within 30 days</u>	<u>Overdue 31 - 60 days</u>	<u>Overdue 61 - 90 days</u>	<u>Overdue 91 - 120 days</u>	<u>Overdue more than 121 days</u>	<u>Total</u>
<u>March 31, 2022</u>							
Expected loss given default	0~2%	6%	21%	43%	50%	100%	
Total book value	<u>\$ 39,147</u>	<u>\$ 4,047</u>	<u>\$ 36</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 15,641</u>	<u>\$ 58,871</u>
Loss provision	<u>\$ 538</u>	<u>\$ 223</u>	<u>\$ 6</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 15,641</u>	<u>\$ 16,408</u>
	<u>Current</u>	<u>Overdue within 30 days</u>	<u>Overdue 31 - 60 days</u>	<u>Overdue 61 - 90 days</u>	<u>Overdue 91 - 120 days</u>	<u>Overdue more than 121 days</u>	<u>Total</u>
<u>December 31, 2021</u>							
Expected loss given default	0~2%	6%	21%	43%	50%	100%	
Total book value	<u>\$ 34,999</u>	<u>\$ 12,182</u>	<u>\$ 577</u>	<u>\$ 76</u>	<u>\$ -</u>	<u>\$ 15,138</u>	<u>\$ 62,972</u>
Loss provision	<u>\$ 527</u>	<u>\$ 697</u>	<u>\$ 93</u>	<u>\$ 33</u>	<u>\$ -</u>	<u>\$ 15,138</u>	<u>\$ 16,488</u>
	<u>Current</u>	<u>Overdue within 30 days</u>	<u>Overdue 31 - 60 days</u>	<u>Overdue 61 - 90 days</u>	<u>Overdue 91 - 120 days</u>	<u>Overdue more than 121 days</u>	<u>Total</u>
<u>March 31, 2021</u>							
Expected loss given default	0~2%	6%	23%	47%	50%	100%	
Total book value	<u>\$ 3,208</u>	<u>\$ 576</u>	<u>\$ 684</u>	<u>\$ 174</u>	<u>\$ -</u>	<u>\$ 15,213</u>	<u>\$ 19,855</u>
Loss provision	<u>\$ 45</u>	<u>\$ 4</u>	<u>\$ 156</u>	<u>\$ 82</u>	<u>\$ -</u>	<u>\$ 15,213</u>	<u>\$ 15,500</u>

H. Below are changes in loss provision on accounts receivable (including related parties), determined using the simplified approach:

	<u>2022</u>	<u>2021</u>
January 1	\$ 16,828	\$ 16,040
Reversal of impairment loss	( 474)	( 247)
Exchange rate impact	<u>453</u>	<u>( 90)</u>
March 31	<u>\$ 16,807</u>	<u>\$ 15,703</u>

Losses reversed during the periods January 1 to March 31, 2022 and 2021, included \$474 and \$247 of losses reversed, respectively, on receivables from contracts with customers.

### (3) Liquidity risk

A. Cash flow projections are made by individual operating entities within the Group, and consolidated by the Group Treasury Department. The Group Treasury Department is responsible for monitoring and predicting liquidity and capital requirements within the Group and ensuring that adequate capital has been sourced to support operational requirements.

B. As of March 31, 2022, December 31, 2021, and March 31, 2021, the Group had undrawn credit limits of \$89,000, \$59,000, and \$86,800, respectively.

C. The following table shows non-derivative financial liabilities and derivative financial liabilities settled on a netted basis, classified by maturity date. Non-derivative financial liabilities are analyzed based on the remaining time span between balance sheet date and contract maturity, whereas derivative liabilities are analyzed based on remaining time span between balance sheet date and expected contract maturity. The amount of contractual cash flow shown in the table below are not discounted.

March 31, 2022

<u>Non-derivative financial liabilities</u>	<u>Within 1 year</u>	<u>1 to 2 years</u>	<u>2 to 5 years</u>	<u>5 years and above</u>
Short-term loans (including estimated interest)	\$ 105,125	\$ -	\$ -	\$ -
Accounts payable	93,315	-	-	-
Accounts payable - related parties	34,597	-	-	-
Other payables	63,624	-	-	-
Long-term borrowings (including current portion maturing in one year and estimated interest)	12,569	12,569	37,708	115,220
Lease liabilities	10,231	4,739	6,329	25,724

December 31, 2021

<u>Non-derivative financial liabilities</u>	<u>Within 1 year</u>	<u>1 to 2 years</u>	<u>2 to 5 years</u>	<u>5 years and above</u>
Short-term loans (including estimated interest)	\$ 105,305	\$ -	\$ -	\$ -
Accounts payable	91,857	-	-	-
Accounts payable - related parties	32,673	-	-	-
Other payables	73,754	-	-	-
Long-term borrowings (including current portion maturing in one year and estimated interest)	12,353	12,353	37,059	116,337
Lease liabilities	11,335	5,897	6,673	27,034

March 31, 2021

<u>Non-derivative financial liabilities</u>	<u>Within 1 year</u>	<u>1 to 2 years</u>	<u>2 to 5 years</u>	<u>5 years and above</u>
Accounts payable	\$ 69,273	\$ -	\$ -	\$ -
Accounts payable - related parties	23,856	-	-	-
Other payables	80,477	-	-	-
Lease liabilities	9,214	7,262	7,756	29,154
<u>Derivative financial liabilities:</u>				
Forward exchange contracts	\$ 116	-	-	-

D. The Group does not expect cash flows in the maturity analysis to occur at an earlier time or in amounts that differ significantly.

(III) Fair value information

1. Valuation techniques and inputs used for measuring fair value of financial and non-financial instruments are defined below:

Level 1 input: Quotations that can be obtained from an active market (unadjusted) on the measurement date for asset or liability of equivalent nature. An active market is one where assets or liabilities are transacted in sufficient frequency and quantity and where price information is provided on an ongoing basis. The fair value of investments in listed shares is determined using this input.

Level 2 input: Inputs can be observed directly or indirectly on an asset or liability, except for quotations covered in level 1 input. The fair value of investments in derivative instruments is determined using this input.

Level 3 input: Inputs that can not be observed for an asset or liability. Investments in equity instruments without an active market are valued using this input.

2. For fair value information of investment properties carried at cost, please refer to Note 6(10).

3. Financial instruments not measured at fair value

Accounts including cash and cash equivalents, accounts receivable (including related parties), other receivables, other financial assets (presented as other current assets), guarantee deposits paid (presented as other current and non-current assets), short-term loans, accounts payable (including related parties), other payables (including related parties), lease liabilities, long-term loans (including current portion due in one year), and guarantee deposits received have book value that closely resembles their fair value.

4. Information on financial and non-financial instruments measured at fair value, classified by asset, liability, nature, characteristics, risks, and levels of fair value input:

(1) Group assets and liabilities by nature:

March 31, 2022	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Assets				
<u>Recurring fair value</u>				
Financial assets at fair value through profit or loss				
Equity securities	\$ 8,269	\$ -	\$ 32,197	\$ 40,466
Financial assets at fair value through other comprehensive income				
Equity securities	-	-	30,806	30,806
	<u>\$ 8,269</u>	<u>\$ -</u>	<u>\$ 63,003</u>	<u>\$ 71,272</u>
December 31, 2021	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Assets				
<u>Recurring fair value</u>				
Financial assets at fair value through profit or loss				
Equity securities	\$ 10,125	\$ -	\$ 36,406	\$ 46,531
Financial assets at fair value through other comprehensive income				
Equity securities	-	-	32,381	32,381
	<u>\$ 10,125</u>	<u>\$ -</u>	<u>\$ 68,787</u>	<u>\$ 78,912</u>

March 31, 2021	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Assets				
<u>Recurring fair value</u>				
Financial assets at fair value through profit or loss				
Equity securities	\$ 5,325	\$ -	\$ 42,364	\$ 47,689
Financial assets at fair value through other comprehensive income				
Equity securities	<u>-</u>	<u>-</u>	<u>2,381</u>	<u>2,381</u>
	<u>\$ 5,325</u>	<u>\$ -</u>	<u>\$ 44,745</u>	<u>\$ 50,070</u>
Liabilities				
<u>Recurring fair value</u>				
Financial liabilities at fair value through profit or loss				
Derivatives				
Forward exchange contracts	<u>\$ -</u>	<u>\$ 116</u>	<u>\$ -</u>	<u>\$ 116</u>

(2) Methods and assumptions used for measuring fair value:

- A. Instruments using market quotation as fair value input (i.e. level 1), distinguished by characteristics:

	<u>TWSE/TPEX listed shares</u>
Market quotation	Closing price

- B. Except for financial instruments traded in active markets, as described above, fair values of all other financial instruments were obtained either by applying valuation techniques or by referring to counterparties' quotations.
- C. For the valuation of non-standardized financial instruments of low complexity, the Group adopts valuation techniques that are commonly used among market participants. Valuation models for this type of financial instrument often use observable market information as the parameter.
- D. Derivatives are valued using valuation models that are commonly accepted among market users, such as the discounted cash flow approach. Forward exchange contracts are usually valued using the prevailing forward exchange rate.
- E. Results generated from the valuation model are approximations of the estimate. The valuation technique may not reflect all relevant factors associated with the holding of financial and non-financial instruments. For this reason, estimates generated from the valuation model are adjusted using additional parameters, such as modeling risks or liquidity risks. Judging by the Group's fair value assessment



modeling policies and control procedures, the management is confident that they ensure a fair presentation for the fair values of financial and non-financial instruments shown on the balance sheet. All valuation adjustments made were appropriate and necessary. All price information and parameters used in the valuation process have been thoroughly assessed and adjusted appropriately according to the prevailing market conditions.

5. There had been no transfer between level 1 and level 2 input during the periods January 1 to March 31, 2022 and 2021.
6. Changes in level 3 input during the periods January 1 to March 31, 2022 and 2021, are explained below:

	<u>2022</u>	<u>2021</u>
	<u>Equity instrument</u>	<u>Equity instrument</u>
January 1	\$ 68,787	\$ 40,642
Recognized through profit and loss (Note 1)	( 4,209)	4,103
Recognized in other comprehensive income (Note 2)	<u>( 1,575)</u>	<u>-</u>
March 31	<u>\$ 63,003</u>	<u>\$ 44,745</u>

Note 1: Presented as other gains and losses.

Note 2: Presented as unrealized gain/loss on valuation of equity instruments at fair value through other comprehensive income

7. There had been no transfer to or from level 3 during the periods January 1 to March 31, 2022 and 2021.
8. The Treasury Department is responsible for validating the fair value of assets that require the use of level 3 fair value input. The department relies on independent sources of information to ensure that the valuation results closely resemble the market condition; it verifies that information is obtained from independent, reliable, and consistent sources; and makes necessary fair value adjustments to ensure that valuation results are reasonable. Furthermore, the Treasury Department has financial instrument fair value evaluation policies and procedures in place and adopts practices to ensure compliance with International Financial Reporting Standards.
9. Quantitative information and sensitivity of significant and unobservable inputs used for level 3 fair value measurement are explained below:

<u>Fair value as of</u> <u>December 31, 2022</u>	<u>Valuation</u> <u>technique</u>	<u>Significant and</u> <u>unobservable</u> <u>input</u>	<u>Range</u> <u>(weighted</u> <u>average)</u>	<u>Relationship</u> <u>between input and</u> <u>fair value</u>
Equity instrument:				

Non-listed shares	\$	30,806	Discounted cash flow method	Note 1	Not applicable	Note 2
Shares of joint venture companies		32,197	Net asset value approach	Not applicable	Not applicable	Not applicable
		<u>Fair value as at December 31, 2021</u>	<u>Valuation technique</u>	<u>Significant and unobservable input</u>	<u>Range (weighted average)</u>	<u>Relationship between input and fair value</u>
Equity instrument:						
Non-listed shares	\$	32,381	Discounted cash flow method	Note 1	Not applicable	Note 2
Shares of joint venture companies		36,406	Net asset value approach	Not applicable	Not applicable	Not applicable
		<u>March 31, 2021 Fair value</u>	<u>Valuation technique</u>	<u>Significant and unobservable input</u>	<u>Range (weighted average)</u>	<u>Relationship between input and fair value</u>
Equity instrument:						
Non-listed shares	\$	2,381	Discounted cash flow method	Note 1	Not applicable	Note 2
Shares of joint venture companies		42,364	Net asset value approach	Not applicable	Not applicable	Not applicable

Note 1: Long-term revenue growth rate, the weighted average cost of capital, long-term pre-tax operating profit, discount for lack of marketability, discount for minority interest.

Note 2: The higher the weighted average cost of capital, discount for lack of marketability, and discount for minority interest, the lower the fair value; the higher the long-term revenue growth rate and long-term pre-tax operating profit, the higher the fair value.

10. The Group exercises a high level of discretion in the assessment and selection of valuation models and parameters. However, the uses of different valuation models or parameters may produce different valuation results. For financial assets classified as level 3 input, impacts on other comprehensive income in the event of a change in valuation parameter are explained below:

	<u>Input</u>	<u>Variation</u>	<u>March 31, 2022</u>		<u>December 31, 2021</u>	
			<u>Recognized in other comprehensive income</u>	<u>Recognized in other comprehensive income</u>	<u>Favorable variation</u>	<u>Adverse variation</u>
Financial assets						
Equity instrument	Weighted average funding cost	±0.5%	\$ 1,350	(\$ 1,250)	\$ 1,750	(\$ 1,600)

#### (IV) Assessment of COVID-19 impact

As per assessment, the spread of COVID-19 and disease control policies imposed by the government had not caused material impact on the Group's operations as of March 31, 2022. Furthermore, the Group has adopted appropriate measures to prevent the effect of COVID-19 on its operations and is closely monitoring future developments.

#### XIII. Other disclosures

##### (I) Information related to significant transactions

Significant transactions undertaken by the Group during the period January 1 to March 31, 2022, as defined in Regulations Governing the Preparation of Financial Reports by Securities Issuers, are explained below; transactions with subsidiaries have been eliminated while preparing the consolidated financial report and are disclosed below solely for reference.

1. Loans to external parties: None.
2. Endorsement/guarantee to external parties: None.
3. End-of-period holding position of marketable securities (excluding investment in subsidiaries, associated companies, and joint ventures): Please refer to Attachment 1.
4. Cumulative purchase or sale of the same marketable securities amounting to NT\$300 million or more than 20% of paid-up capital: None.
5. Acquisition of real estate amounting to NT\$300 million or more than 20% of paid-up capital: None.
6. Disposal of real estate amounting to NT\$300 million or more than 20% of paid-up capital: None.
7. Sales and purchases with related parties amounting to NT\$100 million or more than 20% of paid-up capital: Please refer to Attachment 2.
8. Related party accounts receivable amounting to NT\$100 million or more than 20% of paid-up capital: Please refer to Attachment 3.
9. Derivative transactions: None.

10. Major business dealings between the parent company and subsidiaries and transactions between subsidiaries: Please see Attachment 4.

(II) Information on business investments

Names, locations, and information on investees (excluding Mainland investees): Please see Attachment 5.

(III) Information relating to investments in the Mainland

1. Profile: Please see Attachment 6.

2. Significant transactions with Mainland investees, whether directly invested or indirectly invested through a third location: None.

(IV) Information on major shareholders

Information on major shareholders: Please see Attachment 7.

XIV. Segment information

(I) General information

The Group prepares regional information for its decision makers; regional information is sorted by the locations at which sales orders are received and is currently divided between Taiwan and the USA. Since the two regions differ significantly in terms of sales network, products, and distribution model and operate independently with respect to financial management and performance evaluation, the Group has identified Taiwan and the USA as the reporting segments.

(II) Assessment of segment information

The Group assesses the performance of each segment based on operating revenues. All segments adopt consistent accounting policies, as described in Note 4 - Summary of significant accounting policies of the consolidated financial report. Sales between segments are conducted based on the fair trade principle. Revenues from external sources reported to main decision makers are measured in a manner consistent with revenues of the statement of comprehensive income.

(III) Segment profit/loss

	<u>January 1 to March 31, 2022</u>			<u>Eliminated upon consolidation</u>	<u>Consolidated</u>
	<u>Taiwan</u>	<u>USA</u>	<u>Others</u>		
Income from customers other than the ultimate parent, parent, and consolidated subsidiaries	\$ 194,525	\$206,197	\$ 18,486	\$ -	\$ 419,208
	\$ -	\$ -	\$ -	\$ -	
Income from the ultimate parent, parent, and consolidated subsidiaries	<u>118,077</u>	<u>920</u>	<u>6,575</u>	<u>(125,572)</u>	<u>-</u>
	<u>\$ 312,602</u>	<u>\$207,117</u>	<u>\$ 25,061</u>	<u>(\$125,572)</u>	<u>\$ 419,208</u>
Segment profit/loss	<u>\$ 35,881</u>	<u>(\$ 3,744)</u>	<u>\$ 418</u>	<u>\$ -</u>	<u>\$ 32,555</u>
Segment profit/loss includes:					
Depreciation and amortization	<u>\$ 6,031</u>	<u>\$ 1,068</u>	<u>\$ 617</u>	<u>\$ -</u>	<u>\$ 7,716</u>
	<u>January 1 to March 31, 2021</u>			<u>Eliminated upon consolidation</u>	<u>Consolidated</u>
	<u>Taiwan</u>	<u>USA</u>	<u>Others</u>		
Income from customers other than the ultimate parent, parent, and consolidated subsidiaries	\$ 158,261	\$107,093	\$ 7,923	\$ -	\$ 273,277
Income from the ultimate parent, parent, and consolidated subsidiaries	<u>44,428</u>	<u>54</u>	<u>7,466</u>	<u>( 51,948)</u>	<u>-</u>
	<u>\$ 202,689</u>	<u>\$107,147</u>	<u>\$ 15,389</u>	<u>(\$ 51,948)</u>	<u>\$ 273,277</u>
Segment profit/loss	<u>\$ 6,337</u>	<u>(\$ 3,537)</u>	<u>\$ 839</u>	<u>\$ -</u>	<u>\$ 3,639</u>
Segment profit/loss includes:					
Depreciation and amortization	<u>\$ 4,528</u>	<u>\$ 1,041</u>	<u>\$ 702</u>	<u>\$ -</u>	<u>\$ 6,271</u>

Note: Information on segment assets and liabilities was not provided to key decision makers of the Group, and therefore were not disclosed.

(IV) Reconciliation of segment profit/loss

Sales of merchandise (product) and rendering of service between segments are conducted based on the fair trade principle. Revenues from external sources and financial information reported to main decision makers are measured in a manner that is consistent with the revenues and financial information presented in the statement of comprehensive income. Reconciliation between segment profit/loss and pre-tax profit from continuing operations for the current period:

	<u>January 1 to March 31, 2022</u>	<u>January 1 to March 31, 2021</u>
Net income from reporting segments	\$ 32,137	\$ 2,800
Net income from other reporting segments	<u>418</u>	<u>839</u>
Total across segments	\$ 32,555	\$ 3,639
(Loss) gain on financial assets or liabilities (at fair value through profit or loss)	( 6,065)	3,800
Other gains and losses	25,354	10,404
Financial costs	<u>( 792)</u>	<u>( 156)</u>
Pre-tax profit from continuing operations	<u>\$ 51,052</u>	<u>\$ 17,687</u>

ONYX Healthcare Inc. and Subsidiaries

End-of-period marketable securities holding position (excluding investment in subsidiaries, associated companies and joint ventures)

March 31, 2022

Attachment 1

Unit: NT\$ thousand  
(unless specified otherwise)

<u>Company name</u>	<u>Type of security</u>	<u>Name of security</u> (Note 1)	<u>Relationship with the securities issuer</u> (Note 2)	<u>Account category</u>	<u>Shares</u>	<u>End-of-period</u>		<u>Fair value</u>	<u>Remarks</u> (Note 4)
						<u>Book value (Note 3)</u> (Note 3)	<u>Shareholding percentage</u>		
ONYX Healthcare Inc.	Shares	MACHVISION Inc Co., LTD	Other related party - the Company's Chairman concurrently serves as director in the entity	Financial assets at fair value through profit or loss - current	18,716	\$ 4,061	0.04%	\$ 4,061	None
ONYX Healthcare Inc.	Shares	Top Union Electronics Corp.	None	Financial assets at fair value through profit or loss - current	169,658	4,208	0.17%	4,208	"
ONYX Healthcare Inc.	Shares	Taiwan Star Venture Capital Investment Co., Ltd.	None	Financial assets at fair value through profit or loss - non-current	3,000,000	32,197	13.04%	32,197	"
ONYX Healthcare Inc.	Shares	MELTEN CONNECTED HEALTHCARE INC.	None	Financial assets at fair value through other comprehensive income - non-current	4,193,548	2,381	6.61%	2,381	"
ONYX Healthcare Inc.	Shares	ProtectLife International Biomedical Inc.	None	Financial assets at fair value through other comprehensive income - non-current	2,500,000	28,425	6.30%	28,425	"

Note 1: Securities mentioned in the financial statements shall refer to shares, bonds, beneficiary certificates, and any securities derived from the above, as specified in IFRS 9 "Financial Instruments."

Note 2: Not required if the securities issuer is a non-related party.

Note 3: For items that are measured at fair value, the amount in fair value after adjustment and net of cumulative impairment is shown in the book value column; for items that are not measured at fair value, the amount in original acquisition cost or cost after amortization net of cumulative impairment is shown in the book value column.

Note 4: All securities that have been placed as collateral, borrowed against, or are subject to restrictions under agreed terms shall have details such as the quantity pledged, the amount charged, and restrictions explained in the remarks column.

ONYX Healthcare Inc. and Subsidiaries

Sales and purchases with related parties amounting to NT\$100 million or more than 20% of paid-up capital

January 1 to March 31, 2022

Attachment 2

											Unit: NT\$ thousand (unless specified otherwise)	
<u>Transaction summary</u>											<u>Distinctive terms of trade and reasons (Note 1)</u>	<u>Notes and accounts receivable (payable)</u>
<u>Name of buyer (seller)</u>	<u>Name of counterparty</u>	<u>Relationship</u>	<u>Purchase (sale)</u>	<u>Amount</u>	<u>As a percentage to total purchases (sales)</u>	<u>Loan tenor</u>	<u>Unit price</u>	<u>Loan tenor</u>	<u>Balance</u>	<u>As a percentage of total notes and accounts receivable (payable)</u>	<u>Remarks (Note 2)</u>	
ONYX Healthcare Inc.	ONYX HEALTHCARE USA, INC.	Subsidiary	(Sale)	(\$ 113,154)	(36.20%)	90 days after month-end	\$ -	-	\$ 98,143	47.37%	None	

Note 1: Where the terms of related party transactions differ from ordinary transactions, the discrepancy and causes of discrepancy shall be explained in the unit price and loan tenor columns.

Note 2: In the case of advanced receipt (prepayment), explain in the remarks column the reason, terms & conditions, amount, and deviation from general transaction terms.

Note 3: Paid-up capital refers to that of the Parent company. If the issuer has issued shares without a face value or at face values other than NT\$10 per share, the 20% requirement on paid-up capital shall be calculated instead at 10% of equity attributable to parent company shareholders, as shown on the balance sheet.

Note 4: Disclose the revenue side; no disclosure is needed on the opposing side of the same transaction.



ONYX Healthcare Inc. and Subsidiaries  
 Related party receivables amounting to NTS\$100 million or 20% of paid-up capital or above  
 March 31, 2022

Attachment 3

Unit: NTS thousand  
 (unless specified otherwise)

<u>Companies presented as accounts receivable</u>	<u>Name of counterparty</u>	<u>Relationship</u>	<u>Balance of related party receivables (Note 1)</u>	<u>Turnover rate</u>	<u>Overdue balance of related party receivables</u>		<u>Amount of related party receivables collected after the balance sheet date</u>	<u>Loss provisions provided</u>
					<u>Amount</u>	<u>Treatment</u>		
ONYX Healthcare Inc.	ONYX HEALTHCARE USA, INC.	Subsidiary	\$ 98,143	4.59	\$ -	-	\$ 26,707	\$ -

Note 1: Please input as related party accounts/notes/other receivables.

Note 2: Paid-up capital refers to that of the Parent company. If the issuer has issued shares without a face value or at face values other than NTS\$10 per share, the 20% requirement on paid-up capital shall be calculated instead at 10% of equity attributable to parent company shareholders, as shown on the balance sheet.

ONYX Healthcare Inc. and Subsidiaries

Major business dealings between the parent company and subsidiaries and transactions between subsidiaries

January 1 to March 31, 2022

Attachment 4

Unit: NT\$ thousand  
(unless specified otherwise)

<u>Serial No.</u> (Note 1)	<u>Name of transacting party</u>	<u>Counterparty</u>	<u>Relationship with the transacting party</u> (Note 2)	<u>Account</u>	<u>Transaction summary</u>		<u>As a percentage of consolidated revenues or total assets</u> (Note 3)
					<u>Amount</u>	<u>Transaction terms</u>	
0	ONYX Healthcare Inc.	ONYX HEALTHCARE USA, INC.	1	Sales	\$ 113,154	90 days after month-end	26.99%
0	ONYX Healthcare Inc.	ONYX HEALTHCARE USA, INC.	1	Accounts receivable	9814300.00%	90 days after month-end	4.85%

Note 1: Business dealings between the parent company and subsidiaries are indicated in the serial number column. The numbering rule is explained below:

(1) 0 for the parent company.

(2) Each subsidiary is numbered in sequential order starting from 1.

Note 2: Related party transactions are distinguished into one of three categories, as shown below. Only the category is indicated (no duplicate disclosure is made on two counterparties of the same transaction; for example, in a parent-to-subsidiary transaction, no disclosure is made on the subsidiary's end if disclosure has already been made on the parent company's end; in a subsidiary-to-subsidiary transaction, no disclosure is made on one subsidiary's end if disclosure has already been made on the other subsidiary):

(1) Parent to subsidiary.

(2) Subsidiary to parent.

(3) Subsidiary to subsidiary.

Note 3: Calculation for business dealings as a percentage of total consolidated revenues or total assets is explained as follows: for balance sheet items, percentage of period-end balance is calculated relative to consolidated total assets or liabilities; for profit and loss items, percentage of end-of-period cumulative amount is calculated relative to consolidated total revenues.

Note 4: The Company determines key transactions presented in this chart based on principles of materiality.

Note 5: Individual transactions that amount to less than \$50,000 are not disclosed; disclose the asset or revenue side only. No further disclosure is needed on the opposing side of the same transaction.

ONYX Healthcare Inc. and Subsidiaries

Names, locations and information on investees (excluding Mainland investees)

January 1 to March 31, 2022

Attachment 5

Unit: NT\$ thousand  
(unless specified otherwise)

Name of investor	Name of investee (Notes 1 and 2)	Location	Main business activities	Sum of initial investment		Period-end holding position			Investment gains/losses		Remarks
				End of current period	End of previous year	Shares	Percentage (%)	Book value	Current period profit/loss of the investee (Note 2(2))	recognized in the current period (Note 2(3))	
ONYX Healthcare Inc.	ONYX HEALTHCARE USA, INC.	USA	Sale of medical computers and peripherals	\$ 57,250	\$ 55,360	200,000	100	\$ 94,838	(\$ 2,528)	(\$ 2,528)	None
ONYX Healthcare Inc.	ONYX HEALTHCARE EUROPE B.V.	The Netherlands	Marketing support and maintenance of medical computers and peripherals	3,192	3,132	100,000	100	18,821	957	957	"
ONYX Healthcare Inc.	iHELPER Inc.	Taiwan	Research, development, and sale of medical robots	16,560	16,560	1,656,000	46	7,229	( 713)	( 328)	"
ONYX Healthcare Inc.	Winmate Inc.	Taiwan	Tendering, quotation, and distribution of LCD equipment and modules	552,783	552,783	10,041,000	14	575,109	86,337	11,946	"

Note 1: If the public company has set up a foreign holding entity and prepared a consolidated financial report on the holding entity according to local regulations, information on foreign investees can be disclosed to the level of the foreign holding entity, and no further breakdown is needed.

Note 2: Companies that do not meet the condition described in Note 1 shall complete the form according to the following rules:

- (1) For columns including "Name of investor," "Location," "Main business activities," "Sum of initial investment," and "Period-end holding position," list down investees that are held by the Company first, followed by those held by directly controlled investees and indirectly controlled investees. Specify in the remarks column the relationship between each investee and the Company (such as a subsidiary or 2nd-tier subsidiary).
- (2) For "Current period profit/loss of the investee," specify the amount of profit or loss made by each investee in the current period.
- (3) For "Investment gains/losses recognized in the current period," specify only the amount of profit or loss that the Company has recognized from directly held subsidiaries and equity-accounted investees. No disclosure is needed on indirectly held investees. When disclosing "current gains/losses recognized on directly held subsidiaries," make sure that the gains/losses already include investment gains/losses that they are required to recognize on their investments.

Note 3: Amounts that are denominated in foreign currencies shall be converted into NTD using either the average exchange rate between January 1 and March 31, 2022 for profit or loss items or the exchange rate at the end of the reporting period for all other items.

ONYX Healthcare Inc. and Subsidiaries

Mainland investments - profile

January 1 to March 31, 2022

Attachment 6

Unit: NT\$ thousand  
(unless specified otherwise)

<u>Name of Mainland investee</u>	<u>Main business activities</u>	<u>Paid-up capital</u>	<u>Method of investment (Note 1)</u>	<u>Investment capital contributed or recovered during the current period</u>			<u>Closing cumulative balance of investment capital invested from Taiwan</u>	<u>Current period profit/loss of the investee</u>	<u>The Company's direct or indirect holding percentage (%)</u>	<u>Investment gains (losses) recognized in the current period (Note 2(2)C.)</u>	<u>Closing investment book value</u>	<u>Investment gains recovered to date</u>	<u>Remarks</u>
				<u>Opening cumulative balance of investment capital invested from Taiwan</u>	<u>Invested</u>	<u>Recovered</u>							
Onyx Healthcare (Shanghai) Inc.	Sale of medical computers and peripherals	\$ 62,975	1	\$ 62,975	\$ -	\$ -	\$ 62,975	(\$ 642)	100	(\$ 642)	\$ 7,164	\$ -	None

<u>Company name</u>	<u>Closing cumulative balance of investment capital transferred from Taiwan into Mainland</u>		<u>Limits authorized by the Investment Commission, Ministry of Economic Affairs, for investing in Mainland China</u>	
	<u>China</u>	<u>of Economic Affairs</u>	<u>Investment limit authorized by the Investment Commission, Ministry of Economic Affairs</u>	<u>Investment Commission, Ministry of Economic Affairs, for investing in Mainland China</u>
ONYX Healthcare Inc.	\$ 62,975	\$ 62,975	\$ 62,975	\$ 796,701

Note 1: Method of investment is distinguished between the three categories below, and presented in category name only:

- (1) Direct investment into the Mainland
- (2) Indirect investment into the Mainland through a third location (please indicate the name of the investee at the third location)
- (3) Other method

Note 2: With regards to investment gains/losses recognized in the current period:

- (1) Additional remarks are made for investments that are in the midst of preparation and have yet to produce gains or losses
- (2) Investment gains or losses are specified for having been recognized using one of the following three bases
  - A. Based on financial statements reviewed by the R.O.C. partner of an international CPA firm.
  - B. Based on auditor-reviewed financial statements of the parent company in Taiwan.
  - C. Based on investee's unaudited, non-auditor-reviewed financial statements for the corresponding period.

Note 3: Figures in this chart are presented in NTD.

Note 4: Amounts that are denominated in foreign currencies shall be converted into NTD using either the average exchange rate between January 1 and March 31, 2022 for profit or loss items or the exchange rate at the end of the reporting period for all other items.

ONYX Healthcare Inc. and Subsidiaries

Information on major shareholders

March 31, 2022

Attachment 7

	<u>Name of major shareholder</u>	<u>Number of shares held</u>	<u>Shareholding</u>	<u>Shareholding percentage (%)</u>
	AAEON Technology Inc.	15,132,074		50.00
	Chuang, Yung-Shun	2,361,878		7.80
	ASUSTeK Computer Inc.	1,694,112		5.59

Note 1: Information on major shareholders, as presented in this chart, was taken from records of Taiwan Depository & Clearing Corporation as at the final business day of the reported quarter; and included parties holding book-entry common and preferred shares (including treasury stock) for aggregate ownership of 5% and above.

Share capital reported in the Company's financial statements may differ from the number of shares delivered via book entry due to different basis of preparation/calculation.

Note 2: Shareholders who placed shares under the trust are disclosed in trustors' sub-accounts held with various trustees. According to the Securities and Exchange Act, shareholders with more than 10% ownership interest are subject to insider equity reporting.

Insider equity includes shares held in own name and any shares placed under a trust that the insider has control over. Please access Market Observation Post System for reports on insider equity.